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1 Summary  
Replication of the genome is strongly inhibited when high fidelity DNA polymerases 
encounter unrepaired DNA lesions, which can not be processed. The highly stringent 
active sites of these polymerases are unable to accommodate damaged bases and 
therefore DNA lesions block the replication fork progression. In order to overcome this 
problem, cells have evolved mechanisms for either repairing the damage, or 
synthesising past it with specially adapted polymerasases.  
Eukaryotic DNA polymerase η  (Pol η), belonging to the Y-family of DNA 
polymerases, is outstanding in its ability to replicate through a variety of highly 
distorting DNA lesions such as cyclobutane pyrimidine dimers (CPDs), which are the 
main UV-induced lesions. Also cisplatin induced 1,2-d(GpG) adducts (Pt-GGs), which 
are formed in a typical cancer therapy with cisplatin can be processed by Pol η[1]. The 
bypass of such intrastrand crosslinks by high fidelity DNA polymerases is particularly 
difficult because two adjacent coding bases are simultaneously damaged. Thus, 
replication by Pol η allows organisms to survive exposure to sunlight or, in the case of 
cisplatin, gives rise to resistances against cisplatin treatment. Mutations in the human 
POLH gene, encoding Pol η, causes the variant form of xeroderma pigmentosum 
(XP-V), characterized by the failure to copy through CPDs. This leads to strongly 
increased UV sensitivity and skin cancer predisposition. 
 
This thesis describes mechanistic investigations of the translesion synthesis (TLS) 
process by S. cerevisiae DNA Pol η at atomic resolution, which were undertaken in 
collaboration with the Hopfner group. To study this process, cisplatin lesioned DNA 
had to be prepared first. Once this technique was established, the catalytic fragment of 
Pol η was crystallized as ternary complex with incoming 2',3'-dideoxycytidine 5'-
triphosphate (ddCTP) and an primer - template DNA containing a site specific Pt-GG 
adduct (Figure 1-1 A).  
 
The first obtained structure shows the ddCTP positioned in a loosely bound 
conformation in the active site, hydrogen bonded to the templating base. Realizing the 
importance of the 3’-hydroxy group for positioning the NTP and the DNA correctly 
inside the polymerase, the complex was crystallized again with a 2’-deoxynucleoside 
5’-triphosphate (dNTP). To prevent nucleotidyl transfer, primer strands which 
terminate at the 3’-end with a 2’,3’-dideoxy ribose were prepared by reverse DNA 
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synthesis and used for cocrystallization. The resulting crystals diffracted typically to 
3.1-3.3Å resolution at a synchrotron light source (Figure 1-1 B and C). 
 
 
 
Figure 1-1. A. A cartoon depiction of the Pol η in ternary complex with cisplatin damaged DNA and an 
incoming desoxy nucleoside triphosphate. B. Crystal of Pol η. C. Diffraction pattern of Pol η. 
 
A Pol η specific arginine (Arg73 in yeast Pol η) was identified for its importance to 
position the dNTP correctly in the active site and was shown to be necessary for lesion 
bypass. In contrast to the fixed preorientation of the dNTP in the active site, the 
damaged DNA is bound flexibly in a rather open DNA binding cleft. Nucleotidyl 
transfer requires a revolving of the DNA, energetically driven by hydrogen bonding of 
the templating base to the dNTP. For the 3’dG of the Pt-GG, this step is accomplished 
by bona fide Watson-Crick base pairs to dCTP and is biochemically efficient and 
accurate. In contrast, bypass of the 5’dG of the Pt-GG is less efficient and promiscuous 
for dCTP and dATP. Structurally, this can be attributed to misalignment of the 
templating 5’dG due to the rigid Pt crosslink. 
 
In cooperation with the Cramer group the structural reasons for the blockage of RNA 
Polymerase II (RNAP II) by the cisplatin lesion were elucidated. Using structural as 
well as biochemical methods it could be shown that stalling results from a translocation 
barrier that prevents delivery of the lesion to the active site. AMP misincorporation 
occurs at the barrier and also at an abasic site, suggesting that it arises from 
nontemplated synthesis according to an 'A-rule' known for DNA polymerases. RNAP II 
can bypass a cisplatin lesion that is artificially placed beyond the translocation barrier, 
even in the presence of a G A mismatch. Thus, the barrier prevents transcriptional 
mutagenesis. 
A B 
C 
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2 Zusammenfassung 
Die Verdopplung des Genoms wird stark gehemmt wenn replikative DNA Polymerasen 
auf unreparierte DNA Schäden treffen. Geschädigte Basen können nicht in die 
stringenten aktiven Zentren von „high fidelity“ Polymerasen gedreht werden und 
blockieren die Progression der Replikationsgabel. Um diesem Ereignis 
zuvorzukommen, haben Zellen Mechanismen zur Reperatur und zur fehlerfreien 
Überwindung von DNA Schäden entwickelt. Alle drei Reiche des Lebens verfügen 
über spezielle DNA Polymerasen der Y-Familie, die über Schäden hinweg replizieren 
können und so einen lebenswichtigen Schadenstoleranzmechanismus darstellen. 
Die eukaryotische DNA Polymerase η (Pol η) ist in ihrer Fähigkeit über eine Vielzahl 
von stark DNA Helix verzerrenden Schäden hinweg zu lesen einzigartig. Sie kann zum 
Beispiel Cyclobutan Pyrimidindimere (CPDs), der häufigste UV verursachte Schaden, 
oder die durch das Chemotherapie-Wirkstoff Cisplatin verursachten 1,2-d(GpG) 
Addukte (Pt-GG) hinweg replizieren[1]. Die Replikation solcher Schäden ist besonders 
schwierig, weil zwei aufeinanderfolgende Basen gleichzeitig geschädigt sind.  
 
Somit ermöglicht es die Aktivität von Pol η Organismen die Exposition von 
Sonnenlicht zu tolerieren. Mutationen im menschlichen POLH Gen, welches für Pol η 
kodiert, verursachen die variante Form von Xeroderma Pigmentosum (XP-V). 
Darüberhinaus trägt diese Eigenschaft von Pol η zur Resistenz gegenüber Cisplatin 
basierter Chemotherapie bei. 
 
Im Rahmen dieser Arbeit, welche in Zusammenarbeit mit der Gruppe Hopfner 
durchgeführt wurde, wurde der Mechanismus der „Translesion Synthesis“ (TLS) durch 
S. cerevisiae DNA Pol η auf atomarer Ebene untersucht. Dazu wurde Cisplatin 
geschädigte DNA hergestellt. Diese wurden als Template im Komplex mit dem 
katalytischen Fragment von Pol η, einem ddCTP und Primer kristallisiert 
(Abbildung 1-1 A). 
Bei der Analyse der erhaltenen Struktur zeigte sich, dass das fehlende 3’-OH für die 
korrekte Positionierung des NTPs und somit auch der DNA verantwortlich ist. Um den 
Komplex in einer katalytisch kompetenten Form zu erhalten, wurde die Struktur unter 
Verwendung von dNTPs und eines Primers mit terminaler 2’,3’-Didesoxyribose von 
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neuem mit Auflösungen von 3.1-3.3 Å bestimmt (Abbildung 1-1 B und C). Im Kristall 
liegt der Komplex in zwei Formen vor, wobei bei beiden das dNTP fest im aktiven 
Zentrum gebunden ist. Neben den für Polymerasen üblichen Komplexierung der 
Phosphate durch Metallionen, findet eine für Pol η spezifische Interaktion von einem 
Argenin mit den α- und β-Phosphaten statt. Die Bedeutung der Orientierung des NTPs 
durch diese Aminosäure für die TLS konnte in biochemischen Assays bestätigt werden. 
Im Gegensatz zu der rigiden Positionierung des NTPs interagiert die DNA flexibel mit 
dem Protein und liegt in zwei verschieden gebundenen Positionen im Kristall vor. Der 
Einbau des NTPs erfolgt durch rotierende Bewegung der DNA zum aktiven Zentrum, 
welche durch die Bildung von Wasserstoffbrücken zwischen NTP und Template 
getrieben wird. Der Einbau gegenüber dem 3’dG des Pt-GGs erfolgt durch die Bildung 
von Watson-Crick Wasserstoffbrücken und ist effizient und genau. Im Gegensatz dazu 
ist der Einbau gegenüber dem 5’dG des Pt-GGs weniger effizient und ungenau In 
primer extension assays werden dCTP und dATP gleich gut eingebaut. Strukturell lässt 
sich dies mit einer Fehlstellung des 5’dG vom Pt Crosslink erklären. 
 
In Zusammenarbeit mit der Gruppe Cramer wurden die strukturellen Ursachen für die 
Blockade der RNA Polymerase II durch den Cisplatin Schaden untersucht. Dabei 
kamen sowohl kristallographische als auch biochemische Methoden zum Einsatz. Diese 
Untersuchungen zeigten, dass der Schaden nicht in die aktive Tasche eindringen kann, 
welches zur Blockade des Enzyms führt. Zusätzlich führt die Blockade zum Fehleinbau 
eines AMPs, welcher auch gegenüber einer Abasic site geschieht. Dies scheint der 
A-Regel zu folgen, welche bisher nur für DNA Polymerasen bekannt war. Da die 
Polymerase über einen Schaden, welcher artifiziel nach der translokations Barriere 
platziert wurde, selbst in anwesenheit einer G-A Fehlpaarung hinweg lesen kann, 
verhindert die Blockade die transkriptionelle Mutagenese. 
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3 Introduction 
The cellular DNA is permanently damaged by environmental stress such as UV-light 
and genotoxic agents causing lesion sites. If not repaired, these damages can lead to 
mutations or replication arrest and consequently to cell death or cancer. To maintain the 
integrity of the genome, cells have developed multiple pathways, such as nucleotide 
excision repair (NER) and base excision repair (BER) to overcome different types of 
DNA lesions. Due to constant damage formation there are also lesions present during 
replication of the genome in the S phase, which have not been repaired. These pose an 
obstacle to high fidelity polymerases, which are unable to bypass such lesions in an 
error free manner or are stalled[2]. Low-fidelity polymerases, belonging to the Y-family, 
replace stalled replication machinery and synthesize DNA past the damaged site. Once 
the lesion is overcome, the replicative polymerases then continue with high fidelity and 
processivity[3]. 
Among Y-family polymerases, Pol η is specialized to bypass strongly helix disturbing 
DNA lesions such as ultraviolet-induced cis-syn thymine dimers (TT dimers) or 1,2-
d(GpG) cisplatin intrastrand crosslinks. The translesion synthesis performed by Pol η 
proceeds with remarkable efficiency and accuracy[4-9]. In humans, the replication of 
Pol η through TT dimers establishes besides repair of these lesions a second line of 
defence against sunlight induced skin carcinogenesis, whereas mutations in Pol η cause 
the cancer-prone syndrome xeroderma pigmentosum (XP-V)[7, 9]. The beneficial effect 
of translesion synthesis by Pol η is contrasted during chemotherapy with cisplatin, 
where Pol η allows tumor cells to replicate through intrastrand crosslink. Although this 
lesion is normally repaired by the NER pathway, it is often overseen by the cells’ repair 
mechanisms[10] and thus completely inhibits replicative DNA and RNA polymerases[11, 
12]. Recently it has been shown by in vivo studies that Pol η plays a significant role in 
modulating cellular sensitivity to various anticancer agents and thus contributes to 
acquired drug resistance of cells to cisplatin in cancer chemotherapy[13, 14]. 
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3.1 DNA and DNA damages 
DNA 
Deoxyribonucleic acid (DNA) contains the genetic instructions used in the 
development and functioning of all known living organisms. It is a linear polymer 
made up of four different monomers with a fixed backbone, built of repeating 
deoxyribose-phosphate units. Joined to each deoxyribose is one of four possible bases: 
adenine (A), cytosine (C), guanine (G) and thymine (T) (Figure 3-1.). The sequence of 
bases along a DNA strand constitutes the genetic information, which instructs 
indirectly for assembling proteins, which themselves orchestrate the synthesis of a host 
of other biomolecules such as RNA, sugars, lipids and many others that form cells and 
ultimately organisms[15, 16].  
 
 
 
Figure 3-1. The four nucleotides in DNA. The hydrogen bonds established between the bases are shown 
as black dashes. 
 
DNA exists in several possible conformations including: A-DNA, B-DNA, C-DNA, D-
DNA[17], E-DNA[18], H-DNA[19], L-DNA[17], P-DNA[20], and Z-DNA[21, 22]. However, 
only A-DNA, B-DNA, and Z-DNA (Figure 3-2) have been observed in naturally 
occurring biological systems. The conformation, which DNA adopts, is depending on 
the sequence of the DNA, the amount and direction of supercoiling, chemical 
modifications of the bases and also solution conditions, such as salt concentrations. B-
DNA is viewed as the native structure of DNA, as it prevails in cells, featuring a right 
handed double helix. On the outside of the double helix the spaces between the 
intertwined strands form two helical grooves of different widths described as the major 
groove and the minor groove. 
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Figure 3-2. The three most important DNA secondary structure families in side view (top) and along the 
helix axis (bottom). Left: A-DNA, middle: B-DNA and right: Z-DNA  
 
A-DNA features a shallow and wide minor groove and a narrower and deeper major 
groove and a central hollow cavity. It occurs in dehydrated samples of DNA, such as 
those used in crystallographic experiments, while in the cell it may be produced in 
hybrid pairings of DNA and RNA strands, as well as in enzyme-DNA complexes [23, 24]. 
Z-DNA features a left handed helix with pair wise clustered base pairs and is mainly 
found in CpG alternating sequences or at very high salt concentrations. The major and 
minor grooves, unlike in A- and B-DNA, show little difference in width. 
 
DNA damages 
In all living organisms cellular DNA continually incurs a variety of damage types. In 
the cell, DNA is subject to spontaneous hydrolysis of its phosphodiester, N-glycosylic 
and amino bonds. Moreover DNA is exposed to constant attack by various oxygen 
species and free radicals that damage the sugar and the bases. Exposure to sunlight and 
to chemical pollutants adds further to this load. In total, each cell undergoes about 106 
DNA damages per day[25]. 
The type of DNA damage produced depends on the type of mutagen. For example, UV 
light mostly damages DNA by producing thymine dimers, which are cross-links 
between adjacent pyrimidine bases in a DNA strand. Another example is oxidants, such 
as free radicals or hydrogen peroxide, which produce multiple forms of damage, 
including base modifications, particularly of guanosine, as well as double-strand breaks 
after attackof the sugar. Of these oxidative lesions the most dangerous are double-
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strand breaks, as these lesions are difficult to repair and can produce point mutations, 
insertions and deletions from the DNA sequence, as well as chromosomal 
translocations.  
Many mutagens intercalate into the space between two adjacent base pairs. For an 
intercalator to fit between base pairs, the bases must separate, which distorts the DNA 
superstructure locally because of the unwinding of the double helix at the site of 
intercalation. These structural changes inhibit both transcription and DNA replication, 
causing toxicity and mutations. As a result, DNA intercalators are often carcinogens, 
with acridines and ethidium bromide being well-known examples. Nevertheless, due to 
their properties of inhibiting DNA transcription and replication, some of these 
chemicals are also used in chemotherapy to inhibit rapidly-growing cancer cells. These 
include cisplatin and nitrogen mustards, both belonging to the family of alkylating 
agents. These anticancer agents form crosslinks upon reaction with DNA.  
 
Cells have devised ingenious mechanisms, such as nucleotide excision repair and base 
excision repair processes for repairing and tolerating damages of genomic DNA. 
Failure of these mechanisms can lead to serious disease consequenses, as well 
illustrated in the human hereditary disease xeroderma pigmentosum (XP), hereditary 
non-polyposis colon cancer (HNPCC) and some forms of breast cancer. XP is 
characterized by about a 10.000-fold increased risk of skin cancer associated with 
sunlight exposure, due to impaired nucleotide excision repair processes[26, 27]. 
Individuals with HNPCC manifest an increased hereditary predisposition to colon 
cancer. 
3.1.1 Cisplatin lesions 
cis-Diamminedichloroplatinum(II) (cisplatin) is a potent anticancer drug that is widely 
used to treat testicular, ovarian, head, neck, and small cell lung tumors[10, 28-30]. 
Although cisplatin was approved by the U.S. Food and Drug Administration (FDA) in 
1978 and is one of the most successful anticancer drugs, side effects, natural and 
acquired resistance of patients toward the drug and its limited scope have motivated 
searches for structurally and functionally analogous alternatives[31-34]. These efforts 
include functionalization of ligands[33], bimetallic platinum systems[35] and different 
metal centers, most notably Rh and Ru[36-39]. Unfortunately, finding analogous 
compounds that outperform cisplatin has been proven to be difficult.  
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Figure 3-3. Chemical structures of platinum compounds including marketed platinum anticancer 
drugs[40]. 
 
Over 3000 platinum compounds have been synthesized and tested for their biological 
activity since the discovery of cisplatin[41, 42]. Of these, however, fewer than 30 
compounds have entered clinical trials. At present, only four platinum drugs are 
registered as marketed drugs: cisplatin, carboplatin, oxaliplatin, and nedaplatin. 
Cisplatin, carboplatin and nedaplatin form the same DNA adduct in vivo[43-45]. Until 
recently, a new potentially promising drug belonging to the platinum family of 
compounds was satraplatin[46]. Unlike the platinum drugs currently on the market, 
which all require intravenous administration, it can be administered orally; however the 
drug failed the phase 3 of clinical trials. For an overview of platin based drugs see 
Figure 3-3. 
 Despite its widespread therapeutic use, the mode of action of cisplatin is still not 
completely understood, although the general reaction patterns are largely agreed on[10, 
47-49]. Upon administration, cisplatin encounters a relatively high concentration of 
chloride ions (~100 mM) that suppresses hydrolysis of the two labile chlorido ligands 
that function as leaving groups and maintain the compound in a neutral state. Once 
inside a cell, however, the sharply decreased intracellular chloride concentration of 
around 4-12 mM causes cisplatin to undergo aquation,21 whereby the chlorido ligands 
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are replaced by aqua ligands to form the activated complexes [Pt(NH3)2Cl(H2O)]+ and 
[Pt(NH3)2(H2O)2] +2, which can react more readily with cellular targets (Figure 3-4). 
These complexes bind to various cellular components like DNA, RNA, proteins, and 
membrane phospholipids[50-54]. The major target leading to cell death, however, is 
genomic DNA[10, 55, 56]. Specifically, the N7 atom of purine bases is the main binding 
site, with guanine being preferred over adenine[57].  
 
 
 
Figure 3-4. Schematic representation of cisplatin aquation chemistry in the cell and consequent cellular 
responses to cisplatin lesioned DNA. (Adapted from Kartalou[58]).  
 
The possible binding modes include monofunctional binding to a single purine base, 
intra- and interstrand bifunctional binding, and DNA-protein cross-linking[48]. Due to 
the cis orientation of the leaving groups, intrastrand cross-links between two adjacent 
nucleobases are the most abundant products. The major lesions formed are 60-65% 
intrastrand GG, 25-30% intrastrand AG, 5-10% intrastrand GNG, and 1-3% interstrand 
adducts, with the underlined bases indicating the site of cisplatin binding[59]. Because of 
their abundance, the intrastrand GG adducts are believed to be the major determinants 
of the cytotoxic response to platinum anticancer agents[59-62]. 
 
In the case of the Pt-GG lesion the crosslink formation between two neighboured bases 
alters the DNA superstructure significantly. The lesion causes the adjacent guanine 
bases to roll towards one another, leading to an overall helix bend. In comparison to B-
DNA, the 1,2-intrastrand GG cross-link unwinds the DNA duplex by about 10-20° in 
the vicinity of the site of platination and bends it by 60–80° towards the major groove. 
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This causes a widening and flattening of the minor groove opposite the platinum 
adduct, affording geometric parameters resembling those found in A-DNA[10, 63-65]. 
Structures of duplex DNA containing a 1,2- and 1,3-intrastrand cross-link are 
illustrated in Figure 3-5 A and B respectively.  
 
 
 
Figure 3-5. Platinum-DNA adduct structures and duplex DNA containing (A) cisplatin 
1,2-d(GpG)[65]and (B) 1,3-d(GpTpG) intrastrand[66] cross-links, generated by PyMol. 
3.1.1.1 Effects of Platinum Adducts on DNA Polymerases 
Mammalian cells have the ability to synthesize DNA while ignoring various chemical 
lesions. The process, called translesion synthesis (TLS), demands specialized DNA 
polymerases, which are less stringent than the major replicative DNA polymerases and 
can accommodate damaged bases[67]. Various DNA polymerases have been tested in 
vitro for their ability to replicate past Pt-DNA adducts. The replicative DNA 
polymerases (Polymerases)  α, ε and δ are completely blocked by cisplatin adducts[68, 
69], even in the presence of the accessory proliferating cell nuclear antigen (PCNA) 
protein and replication protein A (RPA)[69]. Polymerases performing translesion 
synthesis past bulky adducts in vivo include members of the X, B, and Y families of 
DNA polymerases[2, 70, 71]. Among the Y-family polymerase, Pol ι, Pol κ, and Pol λ are 
incapable of inserting even a single deoxynucleotide triphosphate opposite cisplatin-
DNA adducts[72-74]. Pol η is by far the most efficient enzyme at translesion synthesis 
past cisplatin- and oxaliplatin-DNA adducts in vitro[75-77]. 
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3.1.1.2 Effects of Platinum Adducts on RNA Polymerase II 
Already in 1974 it was realized that platinum based drugs can inhibit transcription by 
bacterial RNA polymerases[78]. These in vitro studies reported the ability of platinum 
ethylenediamine dichloride and cisplatin DNA adducts to inhibit transcription 
elongation by RNA polymerases[78, 79]. Similar to the inhibition of DNA synthesis, 
RNA polymerases are strongly blocked by bifunctional adducts. They are believed to 
encounter platinum lesions at a relatively early stage in the DNA damage-response 
process, due to their high abundance in the cell. RNA polymerase II (RNAP II), which 
transcribes most eukaryotic genes, is present with about 300 000 copies in a single cell, 
with nearly a fourth constantly involved in transcription[80, 81]. Both, platinum 1,2-
(GpG) and 1,3-(GpTpG) intrastrand cross-links strongly block the elongation complex. 
A cisplatin lesion in the DNA template strand blocks transcription elongation by the 
single-subunit RNA polymerase from phage T7[82] and by RNAP II [11, 83, 84] and leads 
to stable polymerase stalling[85]. The stalled RNAP II elongation complex can be bound 
by the elongation factor TFIIS, which stimulates polymerase back-tracking and 3' RNA 
cleavage[12, 86]. Nucleotide excision repair can then occur in vitro at the DNA damage 
site with the polymerases remaining on the DNA and recruiting repair factors[87, 88]. 
After the repair, RNAP II can re-elongate, although a small fraction of polymerases can 
apparently read through a cisplatin lesion also without repair[11]. Arrested polymerases 
at the site of the platinum lesion not only function as damage recognition factors, 
triggering transcription-coupled repair (TCR)[89], but also mediate programmed cell 
death[90]. 
3.1.2 CPD lesions 
To ensure genetic integrity when living cells are exposed to bright sunlight, nature 
developed several strategies to repair and deal with different types of UV damage. The 
three major lesions generated are cyclobutane pyrimidine dimers, pyrimidine-
pyrimidone (6-4) photoproducts (6-4 PPs), and their Dewar valence isomers[91].  
Of these, the cis-syn cyclobutane pyrimidine dimers (CPD) are the major photoproducts 
induced by UV-B  light (290 nm < λ < 320 nm) present in solar light[92]. The 
photochemical [2+2] cycloaddition reaction involves the C5-C6 double bonds of two 
adjacent pyrimidine bases in DNA to form a cyclobutane ring system (Figure 3-6)[93]. 
Due to the conformation of the bases in double stranded DNA (anti at the glycosidic 
bond) only the cis-syn cyclobutane stereoisomer is obtained. Although both, thymidine 
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and cytidine, can react with each other in all four possible options, the order of reaction 
is 5’-T=T-3’ > 5’-T=C-3’ > 5’-C=T-3’ > 5’-C=C-3’ [94]. Thus, in vivo the cis-syn 
thymine (T=T) dimer is the predominant CPD lesion formed.  
 
 
 
Figure 3-6. Formation of the TT-CPD-lesion by a photochemical [2+2] cycloaddition reaction. 
 
Due to the covalent bonds between two neighboured bases, CPDs are steric demanding 
lesions, causing disturbance of the DNA superstructure. In comparison to B-DNA, 
CPD containing DNA is unwound by ~10° and  the overall helical axis bends ~30° 
towards the major groove[95-98]. This results in a widening of both minor and major 
grooves both 3’ and 5’ of the CPD (Figure 3-7). 
 
 
 
Figure 3-7.  The crystal structure of a DNA decamer containing a TT-CPD lesion. The structure 
is depicted from two different perspectives with the lesion shown in magenta. PDB entry 1N4E. 
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3.1.2.1 Effects of CPDs on DNA Polymerases 
The CPDs mostly exert their detrimental cytotoxic effects by blocking DNA replication 
and transcription and are important players in the formation of skin cancers[99]. 
Although the lesion introduces only a modest deformation of the DNA helix and the 
ability of the two Ts in the dimer to form Watson–Crick base pairs with the As is not 
significantly altered[95-98], a CPD still presents a strong block to DNA synthesis by most 
DNA polymerases, because the covalent linkage of the two Ts in the CPD prevents the 
kinking of the DNA backbone in such a way that the 5’dT of the dimer cannot be 
pushed out of the active site. This then hinders the classical replicative and repair 
Polymerases from replicating through this lesion, because they can accommodate only a 
single templating nucleotide in their active site[100-102]. 
The Y-family DNA Polymerases, on the other hand, can synthesize past DNA lesions, 
but they synthesize DNA with much lower fidelity and processivity than the replicative 
Polymerases. Pol η, for example, has the unique ability to replicate through CPDs 
proficiently and accurately[7, 8].  
3.2 DNA Polymerases 
Possibly the earliest enzymatic activity to appear in evolution was that of the 
polynucleotide polymerases. Faithful replication of DNA molecules by DNA 
polymerases into daughter nucleic acids is essential for genome integrity and stable 
transmission of genetic information in all living organisms and thus a prerequisite for 
known life. On the basis of phylogenetic relationships, DNA polymerases have been 
grouped into six families: A, B, C, D, X, and Y (Table 3-1).  
 
Family Examples Error rate Function 
A Pol I, T7, Taq, Pol γ 10-5 to 10-6 Replication 
B Pol II, Pol α, δ, ε, ζ 10-5 to 10-6 Replication 
C Pol III α subunit 10-5 to 10-6 Replication 
D Pol D 10-5 to 10-6 Replication 
X Pol β, λ, μ, σ 10-4 to 10-5 Repair 
Y DinB, UmuCD, DPO4, Dbd, Pol η, ι, κ, Rev1 10-2 to 10-4 TLS 
 
Table 3-1. Overview of the 6 known DNA polymerase families, their fidelity and function.  
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The A-family is typified by Escherichia coli (E. coli) DNA polymerase I (Pol I), the B-
family by E. coli Pol II, the C-family by the E. coli Pol III α-catalytic subunit, the D-
family by archeal polymerases[103] and the X-family by eukaryotic Pol β. The 
prototypical Y-family polymerases include Pol IV and Pol V in E. coli, which are also 
known as DinB and UmuC respectively, and the eukaryotic Rev1 and RAD30. The 
latter has been renamed Pol η according to the alphabetic convention[104]. 
 
Structures of a number of high-fidelity replicative or repair polymerases have shown 
that they all share a similar architecture, which resembles a cupped right hand with 
palm, fingers, and thumb domains (Figure 3-8).  
 
 
 
Figure 3-8. Structural features of T7 DNA polymerase[100]. The palm (light blue), fingers (green), and 
thumb (dark blue) domains are shown as cartoons. The catalytic center is shown in pink sticks. 
 
In all these polymerases, the palm domain harbours the three conserved acidic residues 
that coordinate the binding of two divalent metal ions. This domain also contributes to 
the binding of the incoming dNTP.  
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3.2.1 Replicative polymerases 
Replicative DNA polymerases are able to replicate the genome at high speed, with high 
processivity and with a very low error rate of about 10-8 to 10-10 per bases replicated[105], 
by using the replication clamp PCNA. To achieve this fidelity, a DNA polymerase must 
have an exceptional ability to discriminate against incorrect base pairs, which may 
exhibit only slight structural and energetic differences from the correct base pair. At 
least three distinct processes contribute to the high fidelity of DNA replication: 
 
 base selection: the DNA polymerization reaction itself has a very low error 
frequency (~10-3 to 10-5).  
 editing: the proofreading reaction by the 3′→5′ exonucleases associated with 
replicative polymerases removes any base that might, on rare occasions, be mis-
inserted. This reduces the error frequency by one or two orders of magnitude. 
 postreplicative mismatch repair: this system further increases DNA replication 
fidelity by approximately another three orders of magnitude. 
 
In high-fidelity replicative polymerases, the finger domain makes intimate contacts 
with the incoming dNTP, and the thumb domain contributes to duplex DNA binding. 
The active site of these enzymes fits very tightly with the templating base, the incoming 
dNTP and a few base pairs in the duplex DNA adjacent to the site of nucleotide 
incorporation. This puts a strong emphasis on the geometric shape complementarity of 
the incoming nucleotide with the templating base[100-102, 106-109]. As a result, geometric 
selection makes a predominant contribution to the nucleotide insertion specificities of 
these polymerases[110-112]. Most importantly, in all these polymerases, only a single 
unpaired template base is held in the active site, while the single-stranded template 
strand, including the next 5 unpaired template base, is flipped out of the active site at a 
90° angle (Figure 3-9)[100-102]. All these features impose a high degree of geometric 
selectivity on the polymerases, which then accounts for their high fidelity. The 
downside to this is that they are highly sensitive to geometric distortions in DNA, and 
thus are unable to replicate through distorting DNA lesions. 
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Figure 3-9. Protein surface representation of the T7 DNA polymerase with the DNA and dNTP depicted 
as sticks, showing how the nascent base pair is enveloped by the protein leaving little room for 
modifications on the templating base[100]. The primer is yellow and the dNTP to be inserted is red. The 
template strand is blue, with the templating nucleotide in olive and the nucleotide to its 5′-side in brown. 
The magnesium ions are depicted as grey spheres. 
 
3.2.2 Low fidelity polymerases 
3.2.2.1 Introduction 
Although most types of DNA damage are removed by the cellular repair machinery, 
these processes are often slow and incomplete. Damages that are not repaired prior to 
the S phase are obstacles for the replication machinery. Most lesions cannot be 
accommodated into the active sites of replicative DNA polymerases; thereby the 
progression of the replication fork is blocked. Prolonged stalling of replication forks 
can lead to a collapse of the replication machinery. This might result in double-strand 
breaks and chromosomal rearrangements, or even to a permanent cell-cycle arrest and 
cell death. To avoid this potential crisis, cells have evolved bypass mechanisms that 
handle stalled replication forks[113].  
 
An important mechanism for overcoming these blocks, particularly in mammalian 
cells, entails the use of specialized lesion bypass DNA polymerases to carry out 
translesion synthesis (TLS) past the damaged sites. Most of these polymerases belong 
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to the Y-family[114]. They all share conserved sequence motifs within the N-terminal 
~350 residues, but their overall length and the C-terminal part vary considerably. The 
conserved active site, located at the N-terminal part of the Y-family polymerases, is 
characterized by a more open active site than in replicative polymerases. The variable 
C-terminus is involved in localization, recruitment and protein–protein interactions 
(Figure 3-10).  
 
 
 
Figure 3-10. Structural domains of the Y-family polymerases. The polymerase domain is labeled in light 
blue (palm), yellow (finger), orange (thumb), green (PAD) and dark blue (N-terminal addition in Pol κ 
and Rev1). The regulatory units are color- and shape-coded as indicated at the bottom of the figure. 
UBM stands for ubiquitinbinding motif, UBZ for ubiquitin-binding zinc finger, and BRCT for Brca1 
C-terminal domain. (Adapted from Yang [115]) 
 
Comparable to the replicative polymerases, the Y-family polymerases also contain the 
domains palm, fingers and thumb; however the last two are smaller and stubby. The Y-
family polymerases bear an additional “little finger” domain, also termed polymerase 
associated domain (PAD) (Figure 3-11). This domain enlarges the potential protein-
DNA interface and enhances DNA binding, which is still rather loose when compared 
to replicative polymerases. Y-family polymerases lack a 3′ → 5′ exonuclease activity, 
which is an integral part of all replicative polymerases. 
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Figure 3-11.  Surface diagrams comparing the structures of several Y-family polymerases. The colours 
of the domains coincide with those used in Figure 3-10. 
 
Because low fidelity polymerases adopt a much more open structure than replicative 
polymerases, they are less stringent and can accommodate altered bases in their active 
sites, incorporating either a correct or an incorrect nucleotide opposite. A downside of 
this “sloppiness” is that translesion synthesis (TLS) is intrinsically error prone. 
 
There are two Y-family polymerases in Escherichia coli (polymerases IV and V), two 
in Saccharomyces cerevisiae (Pol η and Rev1) and four in mammalian cells 
(Polymerases η, ι, κ and Rev1). In addition, the B-family DNA polymerase ζ, which is 
formed by the association of Rev3 and Rev7 proteins, also plays an important role in 
TLS in eukaryotes[116]. These five polymerases used in TLS in human cells have 
different substrate specificities, enabling them to deal with many different types of 
damaged bases[117].  
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3.2.2.2 Polymerase switch 
In order for a TLS polymerase to take over synthesis when a replicative polymerase is 
blocked, the accurate replicative polymerase first needs to be replaced. PCNA plays 
thereby a central role in recruiting the TLS polymerases and effecting the polymerase 
switch from replicative to TLS polymerases[67]. Following replication fork blockage, 
Rad18 (an E3 ligase) binds to exposed single-stranded DNA at the fork and mediates 
together with Rad6 (an E2 ubiquitin conjugating enzyme) mono-ubiquitylation of 
PCNA. The affinity of PCNA for the TLS polymerases, which all have ubiquitin-
binding motifs, is increased, thereby facilitating their engagement at the stalled fork. 
Thus replicative DNA polymerases are replaced and TLS is effected (Figure 3-12).  
 
 
 
Figure 3-12. A proposed mechanism for translesion DNA synthesis. A: A replication fork, consisting of 
PCNA and Pol δ, is stalled when encountering a DNA lesion, for instance, a TT dimer. B: Blockage of 
the fork activates Rad6-Rad18, which mono-ubiquitinate PCNA. C: Modified PCNA then recruits the 
lesion bypass Y-family polymerase Pol η to carry out TLS. D: After the damage has been by-passed, 
replication by Pol δ restarts. (Adapted from Lehmann[67]) 
 
3.2.2.3 DNA polymerase η 
Introduction 
Pol η was first identified in yeast, where it was shown to replicate efficiently through a 
cis-syn thymine dimer by incorporating two adenines opposite the two thymines[8]. This 
observation, which implied that Pol η could promote error-free replication through UV-
induced cyclobutane pyrimidine dimers (CPDs), was in accordance with the 
observation that deletion of the RAD30 gene in yeast conferred an enhancement of UV 
mutagenesis[118]. This previously uncharacterized S. cerevisiae DNA repair gene, 
related to the E. coli dinB, umuC and S. cerevisiae REV1 genes, encodes Pol η.  
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Mutations in human Pol η result in a cancer-prone syndrome, the variant form of 
xeroderma pigmentosum (XP-V)[7-9]. Unlike cells from patients belonging to the 
classical xeroderma pigmentosum (XP) complementation groups, which harbour a 
defect in NER, XP-V cells are proficient in NER but defective in the replication of UV-
damaged DNA[119]. Cells from XP-V individuals are deficient in replication through a 
cis-syn TT dimer, unlike cells from healthy individuals[120, 121]. XP-V cells are 
hypermutable with UV light, and the frequency of adenine incorporation opposite the 
TT photoproducts is reduced in XP-V cells compared to that in normal cells[122, 123]. 
 
Fidelity and Mismatch Extension Ability of Pol η  
Pol η and other Y-family polymerases are able to replicate through DNA lesions since 
they are not inhibited by the geometric distortions imposed by the presence of lesions 
in DNA. The idea that TLS polymerases can better tolerate the geometric distortion of a 
mismatched base pair in their active sites was substantiated from steady-state kinetic 
analyses with yeast and human Pol η, indicating that they misincorporate nucleotides 
with a frequency of ~10-2 to 10-3 [6, 124]. In a subsequent study, human Pol η was shown 
to be highly mutagenic in an in vitro DNA synthesis reaction, making one base 
substitution error for every 18 to 380 nucleotides synthesized depending on the 
mismatch[125]. This very low fidelity indicates a relaxed requirement for correct base 
pairing geometry and indicates that the function of Pol η may be tightly controlled to 
prevent potentially mutagenic DNA synthesis. 
The fact that Pol η incorporates wrong nucleotides at a fairly high rate seems 
incongruous with its role in promoting error-free bypass of CPDs and in suppressing 
UV mutagenesis. However, both yeast and human Pol η extend mismatched primer 
termini with a frequency of ~10-2 to 10-3 relative to extension from matched primer 
termini [126, 127]. Thus, immediately after a misincorporation, Pol η would dissociate 
from the DNA rather than extend from the mispair. The resulting primer-terminal 
mispair then could be subject to proofreading by a 3'→5' exonuclease. Replication 
through a TT dimer by Pol η then would be more accurate than predicted from the 
fidelity of nucleotide incorporation alone[126]. Consequently Pol η would have another 
opportunity to incorporate the correct nucleotide. Such an idea is supported from 
experiments done with the SV40 origin-dependent replication system in human 
extracts, in which it was shown that human Pol η induced replication errors are 
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enhanced if the proofreading exonucleases are inhibited by the addition of high 
amounts of dGMP to the replication reaction [128]. 
 
Lesion Bypass by Pol η  
Pol η is unique among eukaryotic DNA polymerases in its proficient ability to replicate 
through a cis–syn thymine– thymine (TT) dimer. This proficiency of Pol η is derived 
from its unique structural feature - the ability to accommodate both template 
nucleotides of a CPD in its wide and open active site (Figure 3-13)[129].  
 
 
 
Figure 3-13. Structure of the Pol η apoenzyme[129]. The palm (light blue), fingers (green), and thumb 
(dark blue) domains are shown as cartoons. The polymerase associated domain (PAD), uniquely found in 
the Y-family of polymerases is also shown in blue cartoon. The catalytic center is shown as sticks. 
 
Although the proficient ability to replicate through CPDs is the most prominent and 
biologically consequential feature of Pol η, it can promote replication through many 
other DNA lesions, such as Pt-GGs for example, as well. 
 
CPDs   
Pol η replicates through this lesion with the same efficiency and accuracy as it 
replicates through undamaged dTs. Steady-state kinetic studies have shown that both 
yeast and human Pol η insert two As opposite the 3’dT and the 5’dT of the TT dimer 
with the same efficiency and accuracy as they insert two As opposite two normal Ts in 
the undamaged sequence[5, 6]. Moreover, the polymerase exhibits the same processivity 
on the dimer containing DNA as on undamaged DNA. For both undamaged and 
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damaged DNAs, ~50% of the yeast Pol η molecules remain bound after the 
incorporation of two dNTPs opposite the 3’dT and 5’dTs of the dimer or opposite the 
two dTs in the analogous undamaged sequence, and ~30% of the enzyme molecules 
incorporate at least three dNTPs on both DNAs [5]. 
From presteady-state kinetic analyses of the different steps of the nucleotide 
incorporation reaction opposite the two dTs of the dimer, it has been determined that 
yeast Pol η binds the DNA when opposite the 3’dT of the dimer with about the same 
affinity as it binds the analogous site in undamaged DNA[4]. The nearly identical 
efficiency and accuracy of nucleotide incorporation opposite the damaged and 
undamaged dTs strengthens the inference derived from structural studies that Pol η can 
well accommodate both Ts of the dimer in its active site[5, 6, 129]. 
The idea that both Ts of a TT dimer stay in the active site of Pol η rather than the dimer 
being pushed out of the active site, as occurs in T7 polymerase[130-132], has also been 
examined in studies with N3-methyl derivatives of the 3’dT and the 5’dT of a TT 
dimer. These studies added further support to the assumption that both the Ts of the 
dimer remain in the active site and direct the insertion of an A[133]. 
In addition to the formation of CPDs at two adjacent thymines, UV also induces the 
formation of CPDs and (6–4) photoproducts at 5`-TC-3` and 5`–CC–3` sequences in 
the genome. The contribution of these lesions to UV mutagenesis is supported by the 
fact that the 3`-cytosine in both sequences is highly mutagenic and in yeast as well as in 
humans, C to T transitions are the predominant form of UV-induced mutations[134-136]. 
The ability of Pol η to accommodate the two template nucleotides of the TT dimer and 
to incorporate an A directly opposite the two Ts via Watson-Crick hydrogen bonding 
provides an elegant mechanism by which Pol η can also replicate efficiently and 
accurately opposite CPDs at 5'-TC-3' and 5'-CC-3' dipyrimidine sites. Pol η also 
functions in the error-free bypass of CPDs formed at these sites. This is supported by 
the observation wherein inactivation of Pol η in both yeast and humans leads to a large 
increase in the frequency of C to T transitions, which result from the misincorporation 
of an A opposite the 3'C of CPDs at 5'-TC-3' and 5'-CC-3' sites in the absence of 
Pol η[137, 138]. 
CPDs are responsible for a number of UV-induced mutations in mammalian cells. They 
are formed much more frequently than (6-4) photoproducts[134-136, 139-141]. Moreover, 
CPDs are removed much less efficiently than the (6-4) photoproducts by NER[142]. 
Hence, the proficient ability of Pol η to replicate efficiently and accurately opposite 
3 Introduction 
 
 27
CPDs formed at various dipyrimidine sites provides a large measure of protection from 
sunlight-induced skin cancers in humans. 
 
Cisplatin 
Translesion synthesis through cisplatin-DNA adducts has been an interesting aspect of 
DNA synthesis in cisplatin-treated cells because of its correlation to drug 
sensitivity[143]. Cisplatin-resistant cells exhibit more TLS than drug-sensitive cells[144-
146]. Specialized DNA polymerases are overexpressed in many cancer cells and have a 
role in the cellular tolerance to cisplatin DNA damage[13, 147]. The process also plays a 
critical role in conveying the mutagenic properties of cisplatin because of the nature of 
TLS, which carries out both error-prone and error-free DNA synthesis[117]. The 
mutagenicity of cisplatin is closely related to the evolution of resistance of cell lines 
against the drug. In particular, the reduced ability to replicate cisplatin damaged DNA 
decreases the rate at which the cells become resistant to cisplatin. For example, 
suppression of human DNA polymerase involved in TLS, such as polymerase Rev 1[148] 
or Pol ζ[149, 150], increases the sensitivity of cells to cisplatin and reduces the rate of 
appearance of cisplatin resistance.  
 
(6-4) TT photoproducts 
Whereas a cis-syn TT dimer has only a modest effect on DNA structure and retains the 
ability to form Watson-Crick base pairs with the correct nucleotides[95-98], a (6-4) TT 
photoproduct induces a large structural distortion in DNA, with the 3’dT of the (6-4) 
lesion oriented perpendicular to the 5’dT[151, 152]. The O2 carbonyl of the 3’dT in the 
(6-4) TT lesion can hydrogen bond with the imino and amino protons of a guanine (G), 
whereas the 5’dT of the lesion retains the ability to form normal Watson-Crick 
hydrogen bonding with an A[153]. Although both, yeast and human Pol η are unable to 
replicate past a (6-4) TT lesion, they both incorporate a G opposite the 3’dT of the 
lesion about eightfold better than an A.  However, the efficiency of G insertion 
opposite the 3’dT of this lesion is still about 50 to a 100-fold reduced compared to the 
insertion of an A opposite the corresponding undamaged T residue[154]. The subsequent 
extension step opposite the 5’dT is performed by Pol ζ[154, 155]. 
Because (6-4) photoproducts are formed more frequently at 5'-TC-3' and CC sequences 
than at TT sites [134-136, 139-141], the ability of Pol η to insert a G opposite the 3’dT of a 
(6-4) TT lesion strongly suggests that Pol η also contributes to the error-free bypass of 
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(6-4) lesions formed at 5'-TC-3'  and CC sites. Similar to the 3’dT of (6-4) TT, the O2 
carbonyl of the 3’dC in the (6-4) TC and CC photoproducts can also form hydrogen 
bonds with the opposing G. The incorporation of a G opposite the 3’dC of TC and CC 
photoproducts, followed by extension by Pol ζ,  would result in the error-free bypass of 
(6-4) lesions formed at these sites[156]. 
 
8-Oxoguanine  
Whereas the absorption of UV-B and UV-C radiation from sunlight by DNA results in 
the formation of CPDs, (6-4) photoproducts, and other photolesions, the action of 
UV-A radiation from sunlight on cellular chromophores generates reactive oxygen 
species[94, 157]. Hence, exposure of mammalian cells to sunlight produces, in addition to 
CPDs and other photolesions, a significant level of 8-oxoguanine (8-oxoG) lesions. 
Pol η plays a prominent role in efficient and accurate replication through the 8-oxoG 
lesion[158]. The efficiency by which yeast Pol η incorporates a C opposite the lesion and 
then extends from the inserted nucleotide is remarkably similar to that at an undamaged 
G. Evidence for the in vivo role of Pol η in the error-free bypass of the 8-oxoG lesion 
comes from the observation of the rate of spontaneous G:C to T:A transversions, a 
characteristic feature of mutations resulting from the mutagenic bypass of 8-oxoG, is 
synergistically enhanced upon the simultaneous inactivation of Pol η and the Ogg1 
DNA glycosylase, which removes the 8-oxoG paired with a C. Human Pol η also 
predominantly incorporates a C opposite 8-oxoG. However, in this case a low but 
significant level of A is also inserted[158]. 
By promoting error-free replication through the 8-oxoG lesion, Pol η would contribute 
to minimizing the incidence of skin cancers, as well as of internal cancers, that would 
have otherwise resulted from the mutagenic bypass of this lesion by replicative DNA 
polymerases[159]. 
 
Other lesions 
Pol η can replicate through an 6O-methyl guanine (m6G) lesion, but opposite this 
lesion, it incorporates the C and T nucleotides nearly equally well. In contrast to the 
efficient bypass of CPDs and 8-oxoG, replication through the m6G lesion is inhibited 
~20-fold at the nucleotide incorporation step[160].  
An abasic site presents a severe block to replication by Pol η[161]. Even for a G or an A, 
the two nucleotides incorporated most often by Pol η opposite an abasic site, the 
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efficiency of nucleotide incorporation opposite the lesion is reduced by almost 1000-
fold and the extension step is similarly affected[161].  
Pol η is also inhibited by N2-deoxyguanosine adducts of benzo[a]pyrene 
7,8-diol 9,10-epoxide (BPDE)[162], butadiene epoxide[163] and by the acrolein-derived 
adduct γ-hydroxy-1,N2-propano-deoxyguanosine (γ-HOPdG)[164]. Replication by Pol η 
is also inhibited across from 1,N6-etheno-deoxyadenosine[165]. 
 
The ability of Pol η to efficiently replicate through TT dimers, cisplatin lesions, 8-oxoG 
lesions and also to replicate through other helix distorting DNA lesions has indicated 
that Pol η is rather insensitive to geometric alterations conferred on DNA by these 
lesions[161, 164, 165]. However, the efficiency and accuracy of nucleotide incorporation by 
Pol η is impaired by DNA lesions that severely impinge upon the Watson-Crick 
hydrogen bonding of base pairs[166, 167]. In this regard, Pol η differs strikingly from 
classical high-fidelity DNA polymerases. 
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3.3 Eukaryotic RNA polymerase II 
The genetic information encoded in DNA needs to be processed in order to yield 
functional proteins. This process consists of transcribing the genetic information to 
messenger RNA (mRNA) by RNA polymerases. The mRNA is then translated into 
protein by the ribosome. 
Bacteria and archaea contain one such RNA polymerase, whereas in eukaryotes, RNA 
is synthesized by three different types of polymerases, namely RNA polymerase I, II 
and III[168-170]. These three polymerases differ in promoter specificity, localisation in the 
cell and susceptibility to inhibitors. RNAP I transcribes 18S and 28S ribosomal RNA 
(rRNA) and is located in the nucleoli. RNAP III  synthesizes small nuclear RNAs 
(snRNAs), transfer RNAs and the 5.7S rRNA and is located in the nucleoplasm[171]. 
RNAP II, also located in the nucleoplasm, transcribes all mRNAs in the course of gene 
transcription and some snRNAs[172, 173]. RNAP II consists of 12 subunits with a total 
mass of 513 kDa. Sequence analyses showed that two big subunits are highly 
conserved and are the only polypeptides present in all types of cellular RNA 
polymerases[174]. Various biochemical[175-177] and structural studies[178, 179] have shown 
that these highly conserved subunits contain the catalytic center responsible for DNA-
directed RNA transcription.  
 
3.4 Structure determination by X-ray crystallography 
Knowing the three-dimensional structure of a given protein is a big step towards 
understanding the function of the same.  Currently only few techniques are available 
for determining three-dimensional macromolecular structures. Standard light 
microscopy can not be utilized for the visualizing molecules at the atomic level, due to 
the long wavelengths of about 4-8x10-7 m of visible light. At the scale of angstroms, the 
wavelengths needed to analyze atomic distances lie within the spectral range of X-rays. 
Protein crystallography requires large three-dimensional crystals of the sample suitable 
for diffraction of X-rays, which often represents the limiting step. Once obtained, the 
crystals can be measured at in house diffractometers or at synchrotrons. 
Another method that permits analysis at high resolution level of a proteins ternary 
structure is nuclear magnetic resonance (NMR). As NMR allows structural elucidation 
of soluble proteins, it provides information of dynamic processes that cannot be 
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obtained from the rather rigid surroundings of a crystal. However, NMR is limited to 
proteins of small molecular weight of up to 35 kDa.  
At certain speeds, neutrons and electrons can serve as radiation as well. These are 
employed in the electron microscopy technique, which allows elucidation of 
macromolecular surface structures, by focusing the scattered electrons with magnetic 
fields. However the method is limited to a maximal resolution of 6-8 Å due to the poor 
signal-to-noise ratio and the fast damaging of the sample. This makes the method more 
appropriate for very large assemblies, which are difficult to crystallize.  
In summary, although crystallography, when compared to NMR, gives a more static 
description of the macromolecular structures, there are no limits in the size of the 
molecule to be analyzed. This makes X-ray crystallography the method of choice for 
studying macromolecules and their complexes at an atomic level.  
 
3.4.1 Crystallization 
Protein crystallography requires well ordered crystals of the sample suitable for 
diffraction of X-rays. Since proteins are usually large spherical or ellipsoidal objects 
with irregular surfaces, large crystals, wherein the protein is highly ordered in a three 
dimensional array, are quite difficult to obtain. The interactions of the macromolecule 
complex within a crystal are dependent on a plethora of parameters, such as the 
temperature, pH, nature of the solvent, precipitant and salts added, as well as the 
presence of ligands. Moreover, many proteins are composed of multiple functional 
domains with internal or terminal flexible regions. As now commonly believed and 
practiced, one usually attempts to remove all the flexible and non-functional parts and 
retains only the smallest functional domains to facilitate growth of crystals. In 
principle, this approach increases the probability of getting crystals because any 
flexible parts might inhibit the orderly packing of macromolecules in a crystalline 
array.  
All these parameters may inhibit or support crystal growth. In addition, the conditions 
for crystal formation might be different from these optimal for crystal growth. Many 
crystallization conditions have to be tested during a crystallization experiment in order 
to obtain a condition which promotes growth of crystals suitable for X-ray diffraction 
analysis.  
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Crystals form when proteins are precipitated very slowly from supersaturated solutions. 
This thermodynamic driven process includes nucleation, crystal growth and growth 
termination. The most frequently used procedure for obtaining crystals is the vapour 
diffusion method[180]. 
In this thesis, the hanging drop vapour diffusion method was used. Therefore a 
buffered protein solution is mixed with precipitant solution from the reservoir in a 1:1 
ratio on top of a cover slide. The reservoir contains a more concentrated precipitant 
solution and once the reaction chamber is sealed by turning the cover slide over and 
placing it on top of the chamber, slowly equilibrium between the reservoir and the 
hanging drop is reached. This optimally causes a saturation of the protein in the drop 
and if all conditions are right, protein crystals will occur in the drop.  
 
3.4.1.1 Crystallizing a DNA polymerase in ternary structure 
Crystallizing protein-DNA complexes is similar to crystallization of any macro-
molecule. It depends on precipitant, ionic environment, pH and additives. DNA length 
is often the key factor that determines whether a protein-DNA complex crystallizes[181]. 
Since crystals are often grown at room temperature, one needs at least 7 bps to keep a 
DNA duplex stable at 20 °C. DNA sequences starting from the minimal length with 
increments of 1-2 bps can be screened for cocrystallzation.  
Another variable is the sequence of the extra DNA that flanks the central essential 
sequence, particularly bases at the ends of DNA. It is often observed that DNA ends in 
crystals are packed against other DNA ends or protein molecules. Therefore, sticky 
ends, which contain single or double unpaired bases, are often employed so that the two 
ends of a single DNA are complementary. For example, one end has a 5’ protruding T 
and the other end has a 3’ overhanging A. Such DNA can polymerize in a head-to-tail 
fashion to form a repetitive linear array that potentially facilitates crystal growth[182]. 
To capture a DNA polymerase and substrate DNA binary complex, one only needs to 
mix the protein with a DNA that contains both a double-stranded region and a 5’ 
overhanging single stranded region. The junction between the double and single strand 
portions defines a specific site for polymerase to act[102]. For capturing a DNA 
polymerase, DNA substrate and incoming nucleotide in ternary complex, multiple 
approaches to stall the chemical reaction have been applied, which include: 
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 Using a dideoxynucleotide triphosphate as an incoming nucleotide. A number of 
polymerases discriminate against dideoxynucleotide triphosphates, and these 
nucleotide analogs reduce the chemical reaction rate so that an enzyme-substrate 
complex can be captured[183, 184].  
 Using a 3’ dideoxy primer strand, which does not contain an hydroxyl 
nucleophile to form a covalent bond with an incoming nucleotide[100].  
 Replacing Mg2+, which is often essential for a chemical reaction, by Ca2+, which 
enables the DNA and nucleotide association but is ineffective in facilitating 
catalysis[185]. 
  Stabilizing protein-DNA complexes by covalent cross-linking. The basis for the 
design is the hypothesis that a protein α-helix tracks the DNA minor groove 
adjacent to the active site. By systematically replacing residues along that α-helix 
with Cys and modifying the DNA minor groove with a thiol group, a specific pair 
of modified protein and DNA can produce disulfide cross-linked complexes with 
high efficiency, while retaining the native conformation[186]. 
 
3.4.1.2 Crystal Seeding  
If the concentration of a crystallizing protein is plotted against the concentration of the 
crystallizing agent, the resulting diagram divides the space into several areas depending 
on the physical state of the protein (Figure 3-14). 
 
 At very high concentrations of both protein and crystallizing agent, the protein 
precipitates as an amorphous material.  
 At lower concentrations, crystal nuclei may form, which can subsequently grow 
to diffracting crystals.  
 At still lower concentrations, nuclei will not form, so generally no crystals appear. 
However, if a nucleus or crystal is placed in such a solution, it will continue 
growing. This area, where crystals grow but no nucleation takes place, is referred 
to as the metastable zone.  
 At even lower concentrations the protein is completely soluble and nucleuses or 
crystals placed in such a solution dissolve. 
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It is often found that crystals grown in the metastable zone are better ordered and thus 
diffract better than crystals grown at higher concentrations. Also, sometimes it is 
difficult to obtain big enough crystals for diffraction in the nucleation zone, due to 
many but small crystals formed at these conditions. To grow crystals in the metastable 
zone, small crystals acting as nuclei, can be transferred into crystallization drops with 
lower protein and/or precipitant concentration. Crystal seeding can be performed as 
microseeding, by introducing only fragments of crushed crystals, or as macroseeding, 
by transferring an entire crystal to a new drop. 
 
 
 
Figure 3-14. Crystallisation phase diagram. Schematic representation of a two-dimensional phase 
diagram, illustrating the change of protein molecules concentration against precipitating agent 
concentration. The concentration space is divided by the solubility curve into two areas corresponding to 
undersaturated and supersaturated state of a protein solution. The supersaturated area comprises of the 
metastable, nucleation and precipitation zones. 
 
3.4.2 Theory of X-ray diffraction 
X-rays are electromagnetic waves with a wavelength of atomic distances (10-10 m = 
1 Å). For X-ray diffraction experiments of protein crystals, usually X-rays between 0.8-
1.6 Å are used. X-rays interact with electrons in the electron sheath of atoms in the 
protein crystal and cause dipole oscillation of the electrons at the X-ray frequency. The 
oscillating electrons emit X-rays with the same wavelength in every direction (coherent 
or elastic scattering).  
As a crystal is composed of molecules located in a unit cell, which is periodically 
repeated in three dimensions, the emitted waves scattered from different atoms 
interfere, which normally leads to their effacement. Only if waves have a retardation of 
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nλ (n = integer), constructive interference is observed. The retardation is thereby 
dependent on the distance between the scattering atoms. Thus, scattering can be 
described as reflection of imaginary lattice planes. These pervade the crystal lattice and 
its lattice points. Intersections with the unit cell axis of the crystal lattice are termed 
Miller Indices (hkl), which describe the orientation and the spacing between a set of 
parallel lattice planes. The conditions for constructive interference are given by Bragg’s 
Law. 
 
θλ sin2 ⋅⋅=⋅ dn  
 
Only if the distance d between parallel lattice planes and the angle θ between parallel 
lattice planes and the incident beam follow Bragg’s law, a reflexion is observed, and 
results in one reflexion for each set of parallel lattice planes. The conditions of Bragg’s 
law are graphically represented in a Ewald construction[187]. For this, the crystal lattice 
(real space) is transformed into a reciprocal lattice (Figure 3-15). 
 
 
 
Figure 3-15.  Two dimensional Ewald’s sphere construction. The sphere has a radius of 1/λ. The origin 
of the reciprocal lattice is at O. s0 indicates the direction of the incident beam, which is scattered on a set 
of parallel lattice planes with distance d in the real crystal lattice. Scattering is only observed when a 
reciprocal lattice point P intersects with Ewald’s sphere. In this case Bragg’s law is fulfilled and the 
beam scatters into the direction s. 
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Each set of lattice planes can be described by a vector dhkl , having the length hkld  
between neighboring lattice planes and is perpendicular to hkl. According to Braggs 
law, the smaller dhkl is, the bigger is the diffraction angle θhkl, and the resolution. In the 
reciprocal lattice the distance between lattice planes d*hkl = 1/ dhkl , and vector d*hkl is 
also perpendicular to hkl. The end point of vector d*hkl is a lattice point of the reciprocal 
lattice, which is formed by the reciprocal unit vectors a* (a* = 1/a), b* (b* = 1/b) and c* 
(c* = 1/c), whereby a* is perpendicular to hkl (100), b* perpendicular to (010) and c* 
perpendicular to (001). Each lattice point in the reciprocal lattice can be described by 
d*hkl = ha* + kb* + lc* , and corresponds to one possible reflection hkl. According to 
Bragg’s law, a reflection is observed, when a reciprocal lattice point P intersects with 
Ewald’s sphere (radius 1/λ), and the distance between the intersection point P and the 
origin O of the reciprocal (and crystal) lattice (OP) is d*hkl, and the angle between 
crystal M and intersection point P (KP) and crystal M and origin O (MO) is 2θhkl. With 
2sinθhkl = MO/OP (2θhkl = λ/d), Bragg’s law is fulfilled. The diffraction beam results in 
a spot (h,k,l) on the detector. The intensity of the spot can be measured, which 
represents the overall scattering from a particular set of parallel lattice planes. 
As both reciprocal and crystal lattice share the same origin O, the reciprocal is rotated 
with the crystal lattice. If the crystal lattice is rotated 180º around origin O, the 
reciprocal centrosymmetric lattice points will cross the Ewald’s sphere. The lattice 
points d*hkl  and -d*hkl are referred to as Friedel mates. 
 
3.4.3 The Phase problem 
Light detectors, such as photographic plates or charge-coupled devices (CCDs), 
measure only the intensity of the light hitting upon them. This measurement is 
incomplete because a light wave has not only amplitude, but also a phase, which is 
systematically lost in a measurement. In diffraction or microscopy experiments, the 
phase part of the wave often contains valuable information on the studied specimen. 
In x-ray crystallography, the diffraction data give, when properly assembled, the 
amplitude of the 3D Fourier transform of the molecule's electron density in the unit 
cell. If the phases are known, the electron density can be simply obtained by Fourier 
synthesis.  
∑∑∑ ++−=
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3.4.4 Solving the phase problem 
Patterson function 
The Patterson function P(u,v,w) is used to solve the phase problem in X-ray 
crystallography. It is the Fourier transform of F2(h,k,l) and thus can always be 
calculated from the recorded diffraction intensities. The function is defined as: 
[ ]( )lwkvhuF
V
wvuP
h k l
hkl ++= ∑∑∑ π2cos1),,( 2  
In the Patterson function, u, v and w represent the axis of the Patterson cell unit, whose 
dimensions are identical to those of the crystal unit cell x, y and z. Distances between 
atoms in the real structure show up as vectors from the origin to maxima in the 
Patterson cell unit, forming a Patterson map. The maxima are proportional to the 
heights of the peaks in the electron density map. 
 
There are four methods for solving the phase problem: 
1. Multiple isomorphous replacement (MIR) 
2. Multiwavelength anomalous dispersion (MAD) 
3. Molecular replacement (MR) 
4. Direct methods 
 
The availability of a three-dimensional structure of the Pol η apoenzyme allowed solving 
the crystal structures by the molecular replacement method. 
 
Molecular replacement 
The phases are obtained by molecular replacement using a previously solved model 
with sufficient homology to the structure to be determined with help of the Patterson 
function. With the coordinates of the homologous model positioned correctly in the unit 
cell, which is done by rotation and translation of the model, it is possible to calculate 
the amplitudes Fcalc and the phases Φcalc. 
The vectors in the Patterson map can be divided into two categories: intramolecular 
vectors and intermolecular vectors. Intramolecular vectors, which depend only on the 
orientation of the molecule and not on its position in the cell, can be used in the rotation 
function. In this function, the Patterson map of the unknown structure is compared to 
Patterson maps from the model in different orientations. The highest correlation is 
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obtained once the two vectors are in similar orientations. In the subsequent applied 
translation function the model is translated to the correct coordinates in the asymmetric 
unit. For this, the intermolecular vectors can be exploited. These depend on both, the 
orientation of the molecule and on its position in the cell, therefore once the orientation 
of the model is known, the translation function can be applied for correct positioning of 
the model within the asymmetric unit.  
With phases derived from the model and with the experimental observed amplitudes 
Fobs an electron density map is calculated. This model will then have to be carefully 
analyzed and, through several refinement and model rebuilding steps, modified to 
account for the differences between the model and the target molecule in order to 
maximize the agreement with the experimental data. 
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3.5 Research objectives 
The framework of this doctor thesis was to determine how specialized translesion 
synthesis polymerases deal with DNA lesions, which block high fidelity polymerases. 
Cisplatin, a drug used in anticancer therapy, which forms DNA crosslinks mainly at 
sites of two adjacent purines, was chosen to be the model compound. Therefore the first 
research objective was to establish the preparation and purification of the most 
abundant cisplatin DNA intrastrand crosslinks. The 1,2-d(GpG)  and 1,2-d(ApG) 
cisplatin adducts result in a structurally similar lesion, thus emphasis was put on the 
1,2-d(GpG) cisplatin lesion due to its more common occurrence. Another lesion formed 
during cancer therapy is the 1,3-d(GpNpG) lesion, wherein the platinum binds to the 
two guanines usually separated by a thymine. 
Once the lesions could be prepared selectively and site specific, the next step was to 
investigate the lesion bypass mechanism by co-crystallization of the lesion containing 
DNA with a low fidelity polymerase in order to obtain an understanding on the 
molecular basis of the translesion synthesis process past DNA helix disturbing lesions.  
Cisplatin lesions are efficiently bypassed by translesion DNA polymerase η (Pol η) 
which belongs to the Y-family of polymerases. Pol η inserts preferentially two 
cytosines opposite the 1,2-d(GpG)  cisplatin lesion. The polymerase also inserts 
faithfully two As opposite a TT dimer photolesion, thereby playing an important role in 
lesion tolerance. Although the crystal structure of a shortened version of the yeast Pol η 
apoenzyme, lacking regulatory domains, was determined in 2001 so far no structure of 
eukaryotic Pol η in ternary complex with DNA and NTP has been reported in the 
literature. Dpo4, an archeal DinB homolog, capable of replicating past cisplatin lesions 
has been crystallized in ternary complexes with lesion containing DNA and was used 
extensively as a model for eukaryotic DNA Pol η. However there are discrepancies 
upon the validity of this model.  
Thus, the final aim of this work was to crystallize eukaryotic DNA polymerase η in 
ternary complex with a cisplatin lesion containing DNA and incoming nucleotide 
triphosphate and to solve the structure of this complex. This would provide important 
insights into lesion tolerance mechanisms displayed by this recently discovered family 
of DNA polymerases.  
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4 Experimental part 
4.1 Materials 
4.1.1 Chemicals 
Unless otherwise mentioned, the chemicals used had at least analytic purity and were 
provided by Sigma-Aldrich (Deisenhofen), Fluka (Neu-Ulm), BioRad (Munich), Merk 
(Darmstadt), Qiagen (Hilden) and Roth (Karlsruhe). Phosphoramidites and supports for 
DNA synthesis were obtained from Glen Research (Sterling, USA). Crystallization 
screens and reagents were ordered from former NeXtal Biotechnologies (now 
QIAGEN, Hilden) and from Hampton Research (Aliso Viejo, USA).  
4.1.2 Enzymes, Bacterial strains, Standards and Kits  
4.1.2.1 Enzymes  
DNA polymerase η for crystallization and primer extension experiments with cisplatin 
and oxaliplatin lesion containing DNA was kindly provided by Carsten Pieck and 
Claudia Chioccini[188, 189].  
Pfu Turbo DNA polymerase was purchased from Stratagene, Amsterdam, Netherlands. 
 
4.1.2.2 Bacterial strains 
E. coli Strain Genotyp Company 
TOP10 
F- mcrA Δ( (mrr-hsdRMS-mcrBC) φ80lacZΔ(M15 Δ(lacX74 
recA1 araΔ(139 Δ( (ara-leu)7697 galU galK rpsL (StrR) endA1 
nupG 
Invitrogen, 
Karlsruhe 
Rosetta-gami™ 
(DE3)pLysS 
Δ(ara-leu)7697 ΔlacX74 ΔphoA PvuII phoR araD139 ahpC galE 
galK rpsL (DE3) F′[lac+ lacIq pro] gor522::Tn10 trxB 
pLysSRARE (CamR, KanR, StrR, TetR) 
Novagene, 
Schwalbach 
 
Table 4-1. E. coli Strains. 
4.1.2.3 DNA- und Proteinstandards 
Standard Company 
2-Log DNA Ladder (0,1–10,0 kb)    NEB, Frankfurt am Main 
DNA Ladder 1 kb  NEB, Frankfurt am Main 
SeeBlue Plus2 Pre-Stained Protein Standard Invitrogen, Karlsruhe 
 
Table 4-2. Standards. 
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4.1.2.4 Kits 
Name Use Company 
MinElute PCR Purification Kit Purification of PCR products Qiagen, Hilden 
MinElute Gel Extraction Kit Isolation of DNA from agarose gels Qiagen, Hilden 
QIAquick Miniprep Kit Purification of plasmid DNA  Qiagen, Hilden 
QIAquick PCR Purification Kit Purification of PCR products Qiagen, Hilden 
Complete Protease inhibitor Roche, Mannheim 
Gateway-System Cloning Invitrogen, Karlsruhe 
 
Table 4-3. Isolation- und purification kits. 
 
4.1.3 Consumables 
Equipment Company 
Acrodisc 13 mm syringe filter 0.2 μm VWR, Darmstadt 
VDX TM 24 well crystallization plates Hampton Research, Aliso Viejo, USA 
CrystalEX TM 96 well sitting drop plates Corning, New York, USA 
NeXtal DWBlock QIAGEN, Hilden 
CryschemTM 24 well crystallization plates Hampton Research, Aliso Viejo, USA 
Amicon Ultra centrifugal filter devices Millipore, Schwalbach 
 
Table 4-4. Consumables for crystallization and protein/DNA preparation. 
 
4.1.4 Chromatographic material 
Equipment Company 
Sepac-C18 cartridges Waters, Eschborn 
5μ Silica-C18 RP columns Macherey-Nagel, Düren 
7μ Silica-C18 RP columns Macherey-Nagel, Düren 
HiTrap™ Heparin HP Column GE Healthcare, Munich 
Strep-Tactin Superflow cartridge IBA, Göttingen 
 
Table 4-5. Columns for desalting oligonucleotides, HPLC and FPLC separations. 
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4.1.5 Laboratory instruments 
Instrument Company 
Agarose gel electrophoresis chamber Biorad, München 
Äkta Oligopilot 10 Amersham Biosciences 
Autoclave Vakulab S3000 Systec, Gießen 
BioPhotometer 6131 Eppendorf, Hamburg 
Breeze HPLC system Waters, Eschborn 
Bruker Autoflex II (MALDI-TOF) Bruker Daltonik GmbH, Bremen 
Cary 100 UV-Vis spectrometer Varian, Darmstadt 
Centrifuge 5415R Eppendorf, Hamburg 
Centrifuge 5810R Eppendorf, Hamburg 
Cooling trap CT 02-50 Martin Christ, Osterode am Harz 
Electroporator, Micropulser Biorad, München 
Expedite 8900 Nucleic Acid Synthesis System PerSeptive Biosystems, Framingham, MA, USA 
Gel imager IDA Raytest, Straubenhardt 
Gel imager LAS3000 Raytest, Straubenhardt 
Incubator 1S Noctua, Wiesloch 
Incubator 44R New Brunswick, 
Incubator MIR-553 Sanyo, Osaka, Japan 
LaChrom HPLC system Merck-Hitachi, Darmstadt 
Single Channel Pipettes Eppendorf, Hamburg 
Mastercycler Personal Eppendorf, München 
Matrix Hydra II Thermo Scientific, Cheshire, UK 
Mini Protean 3 Cell Biorad, München 
PCR Realplex Eppendorf, Hamburg 
pH meter MP220 Mettler Toledo,Gießen 
       Power Supply          Biorad, München 
Sonicator Bandelin, Berlin 
Sorvall centrifuge, Evolution RC Kendro, Dreieich 
Stereomicroscope Leica MZ16 Leica, Bensheim 
Thermomixer Comfort Eppendorf, Hamburg 
Vacuum concentrator RVC 2-25 Martin Christ, Osterode am Harz 
Vacuum concentrator SpeedVac Savant 
EmulsiFlex-C5 homogenizer Manheim 
Vortex mixer VWR, Darmstadt 
Waterbath Labora, Mannheim 
Waters Millipore System Millipore, Schwalbach 
 
Table 4-6. Instruments used and their manufacturing/distributing companies.  
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4.1.6 Oligonucleotides 
4.1.6.1 Oligonucleotides for crystallization experiments. 
Abbreviation DNA sequence 
eta A 
eta A1 
eta A2 
5’ TCT GGC TCA TCC AC  
         G AGT AGG TG 5’ 
         G AGT AGG TGA 5’ 
eta B 
eta B1 
eta B2 
5’ TCT GGC TCA TCC ACT C 
         G AGT AGG TGA G 5’ 
         G AGT AGG TGA GA 5’ 
eta C 
eta C1 
eta C2 
5’ TCT GGC TCA TCC ACT CAC  
         G AGT AGG TGA GTG 5’  
         G AGT AGG TGA GTG A 5’ 
eta D 
eta D1 
eta D2 
5’ TCT GGC TCA TCC ACT CAC CT  
         G AGT AGG TGA GTG GA 5’    
         G AGT AGG TGA GTG GAA 5’ 
eta E 
eta E1 
eta E2 
5’ TCT CTG GCT CAT CCA C   
            GA GTA GGT G 5’  
            GA GTA GGT GA 5’  
eta F 
eta F1 
eta F2 
5’ TCT CTG GCT CAT CCA CTC  
            GA GTA GGT GAG 5’  
            GA GTA GGT GAG A 5’ 
eta G 
eta G1 
eta G2 
5’ TCT CTG GCT CAT CCA CTC AC   
            GA GTA GGT GAG TG 5’  
            GA GTA GGT GAG TGA 5’  
eta H 
eta H1 
eta H2 
5’ TCT CTG GCT CAT CCA CTC ACC T  
            GA GTA GGT GAG TGG A 5’ 
            GA GTA GGT GAG TGG AA 5’ 
 
Table 4-7. Initial screening for crystals in ternary complex with bound DNA. 
 
 
Abbreviation DNA sequence 
eta O 
eta I 
eta L 
eta I1 
5’ TCT TCT GGC TCA TAC CAC 
5’  TC TCT GGC TCA TAC CAC 
5’   C TCT GGC TCA TAC CAC 
             GA GTA TGG TG 5’ 
eta P 
eta J 
eta M 
eta Q 
eta J1 
5’ TCT TCT GGC TCA CCA C 
5’  TC TCT GGC TCA CCA C  
5’   C TCT GGC TCA CCA C 
5’     TCT GGC TCA CCA C 
             G AGT GGT G 5’ 
eta N 
eta K 
eta S 
eta E1 
5’ TCT TCT GGC TCA TCC AC 
5’   C TCT GGC TCA TCC AC 
5’      CT GGC TCA TCC AC 
             G AGT AGG TG 5’  
eta R 
eta R1 
5’ CTC TGG CTC CCA C 
           GAG GGT G 5’        
eta T 
eta T1 
5’ TCT CTG GCT CAT CCC A 
            GA GTA GGG T 5’  
 
Table 4-8. Refinements of the initial hit (etaE, Table 4-7). 
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4.1.6.2 Oligonucleotides for primer extensions. 
Abbreviation DNA sequence 
DPO4_GG 
GG_comp1 
GG_comp2 
5’ TCT GGA AAT CCT TCC CCC  
         T TTA GGA AGG GGG-fluo 5’ 
        CT TTA GGA AGG GGG-fluo 5’ 
DPO4_GTG 
GTG_comp1 
GTG_comp2 
GTG_comp3 
5’ TCT GTG AAT CCT TCC CCC 
           TTA GGA AGG GGG-fluo 5’ 
         C TTA GGA AGG GGG-fluo 5’ 
        AC TTA GGA AGG GGG-fluo 5’ 
DPO4_CGG 5’ TCC GGA AAT CCT TCC CCC  
eta E1fluo 
eta E2fluo 
eta E3fluo 
eta E4fluo 
               GAG TAG GTG-fluo 5’  
             C GAG TAG GTG-fluo 5’ 
            CC GAG TAG GTG-fluo 5’ 
     A GAG ACC GAG TAG GTG-fluo 5’ 
 
Table 4-9. Oligonucleotides used for primer extension studies with Pol η. The site of the lesion is 
indicated in red letters. Primers are fluorescein labelled. 
 
4.1.6.3 Oligonucleotides for crystallizations 
Abbreviation DNA sequence 
eta Ep1 
 
5’ TCT CTG GCT CAT CCA C   
            GA GTA GGT G 5’  
eta Ep2 
 
5’ TCT TCT GGC TCA CCA C   
            CG AGT GGT G 5’  
eta Ett1 
 
5’ TCT CTT TCT CAT CCA C   
            GA GTA GGT G 5’  
eta Ett2 
 
5’ TCT UCT TTC TCA CCA C   
            AG AGT GGT G 5’  
eta Ett3 
 
5’ CTC UTC TTT CTC ACA C   
            AA GAG TGT G 5’  
Pol2_GG 5'-ACC TCA ACT ACT TGG CCC TCC TCA TT-'3 
Pol2_CGG 5'-ACC TCA ACT ACT CGG CCC TCC TCA TT-'3 
Pol2_IG 5'-ACC TCA ACT ACT TGI CCC TCC TCA TT-'3 
 
Table 4-10. Lesion containg oligonucleotides used for crystallizing Pol η and RNA Pol II in ternary 
complexes. The site of the lesion is indicated in red letters. 
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4.1.6.4 Oligonucleotides for cloning. 
Abbreviation DNA sequence 
Rad30-Gate-N 5’-GGGGacaagtttgtacaaaaaagcaggctTCAT CGAAGGTCGTATGTCAAAATTTACTTGGAAGGAGT-3’ 
Pol η- 513_R 5’-ggggaccactttgtacaagaaagctgggtc TCATTTTTGTAAATCTATAATATCGAAATTAG-3’ 
 
Table 4-11. Primers used for cloning with the Gateway method. The attB site is indicated in small 
letters. 
 
The 2'-deoxyInosin containing oligonucleotide Pol2_IG (table 4-10) was purchased 
RP-HPLC purified and lyophilized from biomers.net (Ulm). All other oligonucleotides 
were purchased RP-HPLC purified and lyophilized from metabion (Martinsried). For 
primer extension experiments the oligomers were 5’-fluorescein labelled. 
 
4.1.7 Buffers, Mediums, Solutions and Antibiotics 
4.1.7.1 Buffers 
Heparin buffers A and B: 
50 mM Tris, 1 mM EDTA, 5 mM DTT and 5% (v/v) glycerol; pH 7.5 
Buffer A: 100 mM NaCl 
Buffer B: 800 mM NaCl 
 
Strep-tag elution buffers A and B: 
Buffer A: 100 mM Tris, 150 mM NaCl, 1mM EDTA; pH 7.5 
Buffer B: 0.5 mg/ml D-Desthiobiotin in buffer A 
 
Crystallization buffer: 
20 mM Tris, 50 mM KCl, 10 mM β–mercaptoethanol and 10% (v/v) glycerol; pH 7.5 
 
Primer extension buffer: 
40 mM Tris, 100 mM KCl, 5 mM MgCl2, 10mM DTT, 2.5% (v/v) glycerol; pH 7.5 
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RP-HPLC buffers A and B: 
Buffer A = 0.1 M NHEt3OAc(aq)  
Buffer B = 0.1 M NHEt3OAc in 80% MeCN(aq) 
 
PBS-buffer: 
140 mM NaCl, 8 mM Na2HPO4, 1.5 mM NaH2PO4; pH 7.2 
 
10 x TBST- buffer: 
100 mM Tris, 1.5 M NaCl, 0.5% (v/v) Tween 20; pH 8.0 
 
Agarosegel- sample buffer:  
50% (v/v) glycerol, 0.2% (w/v) SDS, 0.05% (w/v) bromophenol blue, 0.05% (w/v) 
Xylencyanol FF in TAE- buffer 
 
2 x PAA- sample buffer:  
12% (v/v) Ficoll, 0.01% (w/v) Bromophenol blue, 0.02% (w/v) Xylencyanol FF, 7 M 
urea in TBE- buffer 
 
SDS- sample buffer:  
62.5 mM Tris, 4% (w/v) SDS, 20% (w/v) Glycerol, 5% (w/v) β-mercaptoethanol; 
pH 6.8 
 
SDS- buffer (10x):  
250 mM Tris, 1.92 M Glycerol, 1% (w/v) SDS 
 
TE- buffer: 
10 mM Tris- HCl, 1 mM EDTA; pH 8.0 
 
10 x TBE buffer:  
89 mM Tris, 89 mM boric acid, 20 mM EDTA; pH 8.0 
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4.1.7.2 Media 
LB- Medium: 
1% (w/v) peptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl; pH 7.5 
 
SOC-Medium:  
0.5% (w/v) peptone, 0.5% (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl; pH 7.2 
after autoclaving: 5.0 mM MgCl2, 5.0 mM MgSO4 
 
Medium- Agar : 
Medium with 1.5% (w/v) Agar 
 
4.1.7.3 Solutions 
MALDI matrix: 
3-Hydroxypicolinic acid (50 mg), 15-Crown-5 (10 μl), Ammonium hydrogencitrate 
(10 mg) in ddH2O (1ml) 
 
Staining solution:  
0.25% (v/v) Coomassie Brilliant Blue R 250, 10% (v/v) acetic acid, 40% (v/v) ethanol 
in ddH2O 
 
Destaining solution:  
30% (v/v) ethanol, 10% (v/v) acetic acid in ddH2O 
 
4.1.7.4 Antibiotics and Inducers 
Anhydrotetracycline 2 mg/ml in ethanol 
Carbenicillin 100 mg/ml in ddH2O 
Chloramphenicol 34 mg/ml in ethanol 
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4.2 Methods 
4.2.1 Platinum lesions 
Cisplatin or oxaliplatin lesioned DNA can be obtained by directly allowing oligomers 
to react in solution with the platinum compound. In order to obtain a site specific lesion 
the oligomer has to be designed, so that flanking the site to be platinated no purine 
bases are present at all if possible. Since the GA lesion can not form[190], it is possible 
to have 3’ to the lesion an A in the designed oligomer. Besides the Gs to be platinated 
in the reaction, it is favorable not to have any other Gs in the sequence at all, since 
these can result in monoadducts, which impede the purification process. 
4.2.1.1 1,2-d(GpG) and 1,2-d(IpG) cisplatin lesion containing oligonucleotides 
For obtaining the active aquated cisplatin species, cis-Diamminedichloroplatinum(II) 
(1.5mg) in water (1ml) was incubated with 19 µl of AgNO3 (0.5 M) for 10h at 25 °C. 
The sample was centrifuged in a 5415R Centrifuge for 10 minutes at 10000 rpm in 
order to sediment the AgCl. The activated cisplatin solution (1.5 equivalents) was 
incubated with 100 µM DNA, containing two site specific and adjacent guanines in the 
oligomer sequence for obtaining a site specific 1,2-d(GpG) lesion, or an inosine 
adjacent to a guanine for obtaining a site specific 1,2-d(IpG) lesion, in sodium 
perchlorate buffer (0.1 M, pH 6.0) and mixed  overnight at 37 °C in the dark. The major 
reaction product was purified by HPLC and analysed by matrix-assisted laser 
desorption ionization–time of flight (MALDI–TOF) and contained a single cisplatin 
adduct located at the GG or the IG sequence. 
 
4.2.1.2 1,3-d(GpTpG) oxaliplatin lesion containing oligonucleotides 
Oxaliplatin reacts poorly with DNA in vitro, but its biotransformation product, 
Dichloro(1,2-diaminocyclohexane)platinum(II) (Pt(dach)Cl2) reacts more readily with 
DNA in vitro and forms adducts with the same carrier ligands as those formed by 
oxaliplatin in vivo. Pt(dach)Cl2 (1.9mg) was activated with 19 µl AgNO3 (0.5 M) in 
water (1 ml) for 10h at 25 °C. The platination process is analogous to the one for 
obtaining the 1,2-d(GpG) cisplatin lesion, with the difference that the oligomer contains 
one site-specific GTG sequence. The major reaction product was purified by HPLC and 
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analysed by MALDI–TOF and contained a single oxaliplatin adduct located at the GTG 
sequence. 
 
4.2.2 DNA synthesis, cleavage, purification and hybridization 
DNA oligonucleotides were synthesized on a PerSeptive Biosystems Expedite 8900 
Synthesizer and an Äkta Oligopilot 10 using UltraMILD bases and reagents and 
following standard phosphoramidite protocols (10 equivalents of phosphoramidite (0.1 
M), 4 min recycling and 1 μmol scale synthesis; see Figure 4-1 for the reverse DNA 
synthesis reaction scheme). The phosphoramidite amounts for the 5-Bromo-2'-
deoxyUridine (Br-dU), CPD and 2’,3’-dideoxy nucleosides were equal to those of the 
natural bases but the coupling times were elongated to 15 minutes. While trityl values 
showed good incorporation of the Br-dU and TT dimer nucleosides, the coupling of the 
2’,3’-dideoxy nucleosides could only be verified by MALDI-TOF since these 
terminating nucleosides do not contain a trityl protecting group.  
 
 
 
Figure 4-1. The solid-phase reverse DNA synthesis cycle. 
 
The controlled pore size glass (CPG) solid support was subjected to a concentrated 
ammonia-ethanol (3:1) mixture for 12 h at r.t. for cleavage of the strands terminating 
with 2’,3’-dideoxy nucleosides. The strands containing the Br-dU and CPD nucleosides 
were released from the CPG and deprotected by subjection to conc. NH3 (aq) for 24 h 
at r.t. The solvents were removed in a SpeedVac concentrator and the resulting pellet 
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was redissolved in double destilled water. Subsequent filtration through a 0.2 μm filter 
removed the CPG. Analytics and purification were performed on Merck LaChrome 
HPLC systems using 5μ Silica-C18 RP columns for analytics and 7μ Silica-C18 RP 
columns for purification. For this, a gradient of 0-30% buffer B over 45 min, where 
buffer A = 0.1 M NHEt3OAc(aq) and buffer B = 0.1 M NHEt3OAc in 80% MeCN(aq) was 
used. The purified fractions were concentrated, desalted on Waters Sepac-C18 
cartridges and concentrated again. The concentration of the oligomers was estimated by 
UV spectroscopy following standard procedures on a Cary 100 UV-Vis spectrometer. 
DNA was typically hybridized by depositing equimolar amounts of primer and 
template strand, both in double distilled water, into a vial. The water was evaporated in 
a vacuum concentrator SpeedVac and thereafter the DNA was resuspended in the 
crystallization- or primer extension buffer resulting in a 1 mM solution of dsDNA. 
Next the DNA was hybridized in a PCR Realplex cycler by heating to 85 °C and slow 
cooling to 4 °C. The dsDNA was then stored at 4 °C until use. 
4.2.3 Molecular Biology Methods 
4.2.3.1 Oligonucleotide design and Polymerase Chain Reaction  
PCR primers Rad30-Gate-N and Pol η- 513_R (see Table 4-11) with attB containing 
sites for compatibility with the Gateway technology were used for amplification. As 
template served pDEST007-polη. The PCR reaction conditions are given below. 
 
Reaction conditions: 
2.5 µl 10x buffer 
1 µl template DNA 
1 µl Primer Rad30-Gate-N (10 pmol/µl) 
1 µl Primer Pol η- 513_R (10 pmol/µL) 
0,3 µl Pfu Turbo (2,5 U/mL) 
0.5 µl dNTP mix (10 mM)  
18.7 µl ddH2O 
 
 
 
PCR program: 
1. 95°C 3 min 
2. 95°C 15 sec 
3. 58°C  30 sec 
4. 72°C 5 min 
5. GOTO 2 Repeat 5 
6. 95°C 15 sec 
7. 56°C  30 sec 
8. 72°C 5 min 
9. GOTO 6 Repeat 20 
10. 72°C 10 min
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The PCR product was purified by agarose gel electrophoresis. For this 0.4 g agarose in 
50 ml TBE buffer was dissolved by boiling in a microwave oven. After the solution 
cooled down slightly 8 µl ethidium bromide were added. The gel was run at 95 V.  
The purified DNA was extracted from the gel using the QIAquick PCR Purification Kit 
according to the manufacturers’ protocol. The final DNA concentration was 30 ng/µl. 
4.2.3.2 Cloning 
GatewayTM Technology 
Cloning of PCR products into the vector of choice was undertaken by using the 
Gateway technology, which is based on the site-specific recombination system used by 
phage λ to integrate into and excise from the E. coli chromosome. The attachment sites 
necessary for the homologous recombination event are provided by the PCR products 
and vectors, respectively.  
 
The BP reaction was carried out according to the Invitrogen instruction manual for the 
Gateway™ Technology and contained: 
2 µl PCR-produkt pDEST007-polη513(60ng) 
1 µl pDONR 201 (150 ng/µl) 
5µl TE-buffer pH 8 
2 µl BP clonase 
 
The LR reaction was carried out according to the Invitrogen instruction manual for the 
Gateway™ Technology and contained: 
1 µl pDONOR-η 513 (120 ng/µl) 
1 µl pDEST007 (150 ng/µl) 
6 µl TE-buffer 
2 µl LR clonase 
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4.2.4 Microbiological methods  
4.2.4.1 Bacterial cultures 
Culture of bacterial plates 
Bacterial cultures were added with a sterile spreader onto antibiotic-containing plates. 
The plates were incubated overnight at 37°C. Thereafter plates were stored inverted at 
4°C. 
 
Bacterial overnight cultures 
Over night cultures were grown in LB medium containing the relevant antibiotic in 
either round bottom Falcon tubes or in small Erlenmeyer flasks, allowing for air 
exchange. A cell culture was either picked using a sterile tip from a bacterial plate, or 
taken from a glycerol stock for inoculation. The cell cultures were then incubated over 
night at 37°C, shaking at 250 rpm.  
4.2.4.2 Transformation of electro-competent cells 
The electroporation cuvette was placed on ice, while the electrocompetent cells were 
allowed to thaw slowly on ice. The plasmid preparation to be transformed was also 
placed on ice. Meanwhile 1 ml of SOC medium was warmed in a round bottom Falcon 
tube to 37°C.  1 μl of plasmid DNA was mixed gently with 50 μl cells and incubated on 
ice for 1 min. The cells were transfered to the pre-cooled cuvette, and electroporated 
(2.5 kV, 3ms). Immediately afterwards the cells were transferred to the SOC medium 
and incubated for 1 hour shaking at 37°C. The cells were harvested after centrifugation 
at 4000 x g for 2 min and spread on a bacterial plate containing the relevant antibiotics 
for selection. 
4.2.4.3 Transformation of heat competent cells 
Transformation of plasmid DNA into heat competent E.coli TOP10 cells was 
performed by mixing 50 μl of competent cells with 1 μl of purified plasmid DNA for 5 
minutes on ice. Cells were incubated at 42°C for 30 seconds and then immediately 
chilled on ice for 2 minutes. 250 μl of fresh LB medium was added, followed by 
incubation at 37°C for 1 hour in a thermo shaker. Cells were plated on LB-agar plates 
containing the respective antibiotics and incubated at 37°C overnight. Plasmid DNA 
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was isolated from a 3 ml overnight culture using the QIAquick Miniprep Kit. DNA-
sequencing of the clones after the BP reaction was performed by GATC-Biotech, 
Konstanz. 
 
4.2.5 Protein biochemical methods  
4.2.5.1 Protein expression 
An overnight bacterial cell culture was grown in 60 ml LB medium containing 100 
μg/ml carbenicillin and 34 μg/ml chloramphenicol. Ten ml of this culture were added 
to 2 l Erlenmeyer flasks containing 1 l LB medium with 100 μg/ml carbenicillin and 34 
μg/ml chloramphenicol. Six flasks were prepared in this manner, incubated at 37°C and 
shaken at 250 rpm until the optical density of the cells reached 0.6 at a wavelength of 
600 nm against a blank of LB medium. At this point the temperature was decreased to 
16°C and gene expression was induced by the addition of 0.2 μg/ml anhydrotetracyclin. 
Optimal expression of Pol η was achieved after 4-5 hours. The cells were then 
harvested by centrifugation at 8000 rpm for 12 min at 4°C and stored as pellets at -
20°C until purification.  
Before and after induction 100 μl samples were taken from the culture. The cells were 
pelleted and redissolved in 100 μl SDS sampling buffer after discarding the 
supernatant. The sample was then heated at 85°C for 10 minutes and afterwards stored 
at -20°C. 
4.2.5.2 Cell rupture 
The pellet of cells having expressed Pol η was redissolved in cold Strep-tag elution 
buffer A together with an added tablette of Protease Inhibitor Complete (without 
EDTA). For rupture the cells were passed through a high pressure cell homogenizer at 
10000 psi 3-4 times. The suspension was then transferred into Oak Ridge centrifuge 
tubes and centrifuged at 18000 rpm for 30 min at 4°C in a Sorvall SS-34 rotor for 
removal of insoluble proteins and cell debris. After harvesting the supernatant this step 
was repeated and finally the supernatant was filtered through sterile 0.2 μm filters 
before being subjected to further protein purification on an Äkta FPLC system. 
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4.2.5.3 Protein purification 
The protein solution was loaded onto a Strep-Tactin Superflow column. Proteins not 
bound were eluted by washing with 3.5 CV Strep-tag elution buffer A (1ml/min). The 
bound protein was released by eluting with 100% Strep-tag elution buffer B (1ml/min). 
The Pol η containing fractions were pooled, reduced to 500 µl in an Amincon Ultra 
centrifuge filter device at 4000 rpm and the buffer exchanged against Heparin buffer A 
by 5 ml addition of the same to the centrifuge filter and repetitive reduction to 500 µl. 
The protein was loaded onto a HiTrap™ Heparin HP ion exchange column which was 
washed with 5 CV Heparin buffer A for eluting DNA. Pol η was eluted with a linear 
gradient over 10 CV from 100% Heparin buffer A to 100% Heparin buffer B.  
After the second step of purification the Pol η containing fractions were pooled and 
reduced to 500 µl in an Amincon Ultra centrifuge filter device at 4000 rpm. 5 ml of 
crystallization buffer were added and the protein was again reduced to 500 µl. This step 
was repeated twice and the polymerase was concentrated to at least 7 mg/ml. The 
protein preparation was aliquoted into 15 µl samples, shock frozen with liquid nitrogen 
and stored at -80°C until further use. 
4.2.6 Primer extension assays 
The 5’ fluorescein labeled primers were annealed to the unlabeled templates containing 
a site specific lesion and to undamaged templates in the primer extension buffer at a 
molar ratio of 1:1.5 in order to ensure that all labeled primers are hybridized. Primer 
extension studies were carried out, unless otherwise specified, by incubating Pol η 
(0.25 µM) with 1 µM primer-template substrate and dNTP (200 µM) in the primer 
extension buffer. The reaction mixtures (30 µl) were incubated at 26 °C and the 
reaction was stopped by adding 50 mM EDTA pH 8.0. Quenched samples were heated 
to 95 °C for 3 min and analyzed by electrophoresis on denaturizing 22.5 % acrylamide 
gels, containing 7.5 M urea. Resolved extension products were detected by using a 
LAS-3000 imaging system. 
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4.2.7 Crystallization 
4.2.7.1 DNA screening 
Prior to the crystallization setup, the ternary complex was allowed to form by 
incubating dsDNA (0.24 mM) with ddCTP (1 mM), MgCl2 (5 mM) and protein 
(6 mg/ml) at room temperature for 10 minutes. 13-22 base pair template DNA strands 
with complementary primer strands (Table 4-7) yielding sticky ends of 5-8 bases with 
or without a 1 base overlap at the 3’ template strands were screened for 
cocrystallization with Pol η utilizing commercial NeXtal DWBlock Suite sparse matrix 
screens (Qiagen) in CrystalEX 96 well sitting drop plates. Setups were pipeted by a 
Hydra II semi-automatic protein crystallization robot (0.2 μl protein + 0.2 μl 
precipitant).  
After obtaining an initial hit with eta E and the complementary primer eta E1, DNA 
strands containing 7-10 bp double strands with various lengths of overhangs were 
tested for yielding even better crystals (Table 4-8).  
4.2.7.2 Crystallization of Pol η with lesion containing DNA and ddCTP 
The first tetragonal crystals of the Pol η – dsDNA - ddCTP complex were obtained 
from solutions containing 20% PEG 3350 and 200 mM calcium chloride, at 18°C by 
vapour-diffusion using the sitting drop method. Prior to the crystallization setup, the 
ternary complex was allowed to form by incubating dsDNA (eta Ep1, Table 4-10) (2.5 
equivalents) with ddNTP (1 mM), MgCl2 (5 mM) and protein (6 mg/ml) at room 
temperature for 10 minutes.To improve crystal quality the conditions of the initial hit 
were refined by varying the protein concentration, concentrations of the components of 
the crystallization buffer, pH, temperature, drop size, mixing ratio between drop and 
precipitant and reservoir volume in 24 well formats either in sitting drop VDXTM plates 
or hanging drop Cryschem plates. 
The biggest crystals appeared overnight in wells containing 2 μl droplets (1 μl of 
protein-DNA complex with 1 μl reservoir solution) and 100 µl of precipitant solution 
(160 mM calcium chloride and 16% (w/v) PEG 3350) and achieved maximum size after 
about 2-3 days using the hanging drop vapour-diffusion method at 18ºC. 
Repetitive macro seeding was required to produce diffraction quality crystals. To do so, 
a crystal was fished out of the well, washed twice in precipitant solution for removing 
any potential present microcrystals and placed in a new 2 µl droplet. This procedure 
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was repeated at least 3 times, until the crystal reached its final size of approximate 
dimensions of 0.2 × 0.1 × 0.1 mm. 
4.2.7.3 Crystallization of Pol η with lesion containing DNA and dNTP 
Crystals of the Pol η – dsDNA - dNTP complexes were obtained by manually mixing 
1 μl protein solution and 1 μl precipitant, setting up hanging drops and performing 
macro seeding as described in 4.2.7.2. Prior to the crystallization setup, the ternary 
complex was allowed to form by incubating dsDNA (2 equivalents) with dNTP 
(1 mM), MgCl2 (5 mM) and protein (4.5 mg/ml) at room temperature for 10 minutes. 
The dsDNA used was a 2’,3’-dideoxy primer strand (4.2.2) hybridized in an equimolar 
ratio to a site specific lesion containing template strand.  
Cryocooling was achieved by soaking the crystals for 5-10 seconds in reservoir 
solution containing 15% D(-)-2,3-butanediol and flash-freezing in liquid nitrogen.  
 
4.2.8 Data collection and processing 
Redundant single wavelength anomalous dispersion (SAD) data at the platinum LIII 
absorption edge wavelength were collected at beamlines PX-1 at SLS (Swiss Light 
Source, Villingen, Switzerland), ID23-2 at ESRF (European Synchrotron Radiation 
Facility, Grenoble, France) and PX-14.1 at BESSY (Berliner Elektronenspeicherring-
Gesellschaft für Synchrotronstrahlung). Best wavelengths for the peak were determined 
by fluorescence scan on each crystal. 
 
4.2.9 Structure solution and refinement 
Data were processed with the XDS suite[191]. Initial phases were determined by 
molecular replacement method with the program Phaser[192] using the coordinates of the 
Pol η apoenzyme structure (1JIH)[129] as a search model. The topology and parameter 
data of the cisplatin lesion for refinement were generated from coordinates 1CKT[193] 
using XPLO2D[194]. All manual model building steps were performed with MAIN[195] 
and COOT[196]. After corrections for bulk solvent and anisotropic overall B-values, the 
model data was refined by iterative cycles of simulated annealing, positional 
refinement and individual B-factor refinement with the program CNS[197]. Initial non 
crystallographic symmetry (NCS) restraints were gradually removed in the final cycles 
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of the refinement, to allow some structural variations. Data collection and model 
statistics are summarized in Tables 7.1 and 7.2. PROCHECK[198] revealed no 
disallowed angles and good stereochemistry for the final model which comprises 509 
residues.  
4.3 Bioinformatic Methods 
4.3.1 Homology searches and alignments 
Protein sequences were retrieved from the National Center for Biotechnology 
Information (NCBI) database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein). 
Multiple sequence alignments were performed with ClustalW (http://align.genome.jp/) 
and edited manually for structure based sequence alignments. 
 
4.3.2 Structure visualization and analyzing 
Least-squares superpositioning of polymerases were performed with LSQMAN[199], 
using the Cα atoms of the Palm residues for search models. Figures for visualization of 
the crystal structures were prepared with PyMol[200]. Difference distance matrix plots 
were produce using the DDMP program from the Center for Structural Biology at Yale 
University, New Haven, CT. 
 
4.3.3 Crystallographic software 
XDS[191] 
Phaser[192] 
XPLO2D[194] 
MAIN[195] 
COOT[196] 
CNS[197] 
PROCHECK[198] 
LSQMAN[199] 
PYMOL[200] 
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5 Results 
5.1 Preparation and purification of platin lesion containing DNA 
strands 
The DNA templates DPO4_GG, DPO4_GTG and DPO4_CG (Table 4-9) were 
prepared for primer extension experiments, whereas the DNA templates eta Ep1 and 
eta Ep2 (Table 4-10) were prepared for cocrystallizations with Pol η. The DNA 
templates Pol2_GG, Pol2_CGG and Pol2_IG (Table 4-10) were prepared for a 
collaboration with the group of Prof. Cramer. All strands were prepared according to 
the procedures described in 4.2.1. When platinating a commercial strand (Es1, Figure 
5-1), besides the sought after product, other side products such as strands with 2 or 
more bound platinums are obtained (crude, Figure 5-1).  
 
Figure 5-1. HPLC spectra of the unplatinated strand (Es1), unpurified reaction mixture (crude) and the 
platinated strand (Ep1) are overlayed on the left. On the right the MALDI-TOF spectra of Ep1 is shown 
(calculated 4997 amu).  
 
After purification of the main product by HPLC the strands were approximately 99% 
pure and did not contain contaminations of unplatinated strands, which would falsly 
contribute to primer extensions (Ep1, Figure 5-1). The high purity of the strands is also 
of importance for crystallization setups, where impurities could inhibit crystal growth. 
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5.2 DNA synthesis and purification  
5.2.1 Preparation and purification of 2’,3’-didesoxy primer strands  
The complementary primer strands of  eta Ep1/2 and eta Ett 1/2/3 (Table 4-10) were 
synthesized with 2’,3’-dideoxybases at the 3’end using 5’-CE-phosphoramidites. The 
strands were subsequently purified by HPLC as described in 4.2.2 (Figure 5-2).  
 
 
 
Figure 5-2. HPLC spectra of the unpurified synthesis product (crude) and the purified strand (purified) 
are overlayed on the left. On the right the MALDI-TOF spectra of the purified strand is shown 
(calculated 2779 amu).  
 
By utilizing these primers for crystallization, the nucleotidyl transfer is inhibited due to 
the lack of the primers 3’-OH group. Thus, the Pol η – DNA – dNTP complex can be 
crystallized with the polymerase trapped at a defined position relative to the lesion.  
5.2.2 Preparation and purification of TT dimer lesion containing DNA 
strands 
The DNA templates eta Ett1, eta Ett2 and eta Ett3 (Table 4-10) were synthesized for 
cocrystallizations with Pol η. The chemical analog of the TT dimer, which was used for 
DNA synthesis, contains a formacetal linkage instead of the intradimer phosphate, 
which is highly useful in preparing the CPD lesion analog in quantities sufficient for 
crystallization studies. The strands were prepared according to the procedures described 
in 4.2.1. and after HPLC purification a purity of approximately 99% was obtained.  
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Figure 5-3. HPLC spectra of the unpurified synthesis product (crude) and the purified strand (purified) 
are overlayed on the left. On the right the MALDI-TOF spectra of the purified strand is shown 
(calculated 4734 amu).  
 
5.3 Primer extensions of 1, 3 GTG oxaliplatin adducts 
Template strand DPO4_GTG (Table 4-9) was prepared as described in 4.2.1.2 and 
purified by HPLC as described in 4.2.2. The template strand was annealed to the 5’ 
fluorescein primer strands GTG_comp 1/2/3 in the reaction buffer in a 1:1.5 ratio in 
order to ensure that all primer strands anneal. In order to evaluate the capability of 
Pol η to copy through a DNA strand containing a 1,3 GTG oxaliplatin adduct, primer 
extension experiments were performed as described in 4.2.6 with the following 
alterations: Increasing concentrations of Pol η were incubated for 20 min with dNTPs 
(100 μM) at 25 C°. 
 
-N N+1 fullextention
1 2 3 4
Template   5’- TCTGTGAATCCTTCCCCC
Primer                             TTAGGAAGGGGG -5’
5 6 7 8  
 
Figure 5-4. Concentration dependent primer extension studies with Pol η and DNA containing a site 
specific oxaliplatin adduct. In lane 1 the unextended primer (N), lane 2 the first extension (N+1), lane 3 
the full extension product and in lanes 5 – 8 the reaction products obtained with decreasing 
concentrations of Pol η (112x103/112x102/1120/112 nM).  
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Once it was shown that Pol η can perform a full extension of GTG_comp 1 (Figure 
5-4), the specificity of incorporation opposite the various damaged bases was evaluated 
(Figure 5-5). GTG_comp 1 was used for studying the incorporation opposite the lesions 
3’dG, GTG_comp 2 for the dT flanked by the two dGs and GTG_comp 3 for the 5’dG. 
The primer extension studies were performed as described in 4.2.6 with the following 
alterations: Pol η (120 nM) was incubated for 15 min with 1 µM primer-template 
substrate and dNTP (100 µM) in the primer extension buffer at 35 C°. 
 
 
 
 
 
Figure 5-5. Primer extension studies with 
DPO4_GTG and primers terminating at the 
different positions opposite the lesion. The 
specificity of dNTP incorporation opposite 
the 3’ (A), T (B) and 5’ (C) bases of the 
lesion was probed. 
 
Primer extension studies with DPO4_GTG and GTG_comp 1 revealed that Pol η 
inserts opposite the 3’dG mainly a dCTP in the absence of the lesion (Figure 5-5 A). 
Opposite a lesioned base as well mainly a dCTP was inserted. 
Opposite the dT between the dGs, Pol η mainly inserts a dATP and to a much lesser 
extent dTTP and dGTP in the absence of the lesion. Mainly a dATP but also dGTP and 
dTTP were inserted in the case of a lesion present (Figure 5-5 B). 
For the 5’dG mainly a dCTP and to a lesser extend a dTTP insertion in the absence of 
the lesion was observed. Opposite the lesioned base mainly a dCTP was inserted 
(Figure 5-5 C). 
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5.4 Crystallization of DNA Pol η in ternary structure 
5.4.1 Preliminary screenings 
The Pol η apoenzyme structure was solved in 2001[129], but no structure of this 
polymerase in ternary complex with the substrates was obtained subsequently. 
We rationalized that Pol η, being a TLS polymerase, might be easier to be trapped in 
ternary complex by using a lesion containing DNA for cocrystallization experiments. 
Therefore we screened for crystal growing conditions as described in 4.2.7.2 using the 
cisplatin lesion containing DNA strand DPO4_GG (Table 4-9). The first microcrystals 
were obtained in conditions containing 0.2 M magnesium acetate and 20 % Peg 3350 
w/v and were further optimized for obtaining diffracting crystals (Figure 5-6). 
 
  
 
Figure 5-6. Microcrystals of Pol η with cisplatin lesion containing template – primer DNA strand 
DPO4_GG, which grew in the initial hit (left) and a crystal grown after refining the initial conditions 
(right).  
 
The obtained crystals defracted to a limiting resolution of 2.4 Å, but after solving and 
analyzing the structure we realized that we did not obatin a structure of the ternary 
complex, since the polymerase did not contain DNA (Figure 5-7). 
Next we decided to screen different DNAs, assuming that another factor for obtaining 
crystals of the ternary complex might be the length and/or sequence of the DNA to be 
crystallized. In order to test many different oligomers for cocrystallization rapidly, we 
decided to use undamaged oligomers for the initial screens (Table 4-7).  
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Figure 5-7. The Fo-Fc difference electron density shown in red after the initial molecular replacement 
with the Pol η apoenzyme[129], which was used as the model for replacement, depicted as a cartoon. The 
catalytic center is shown in magenta sticks for ease of orientation. 
 
After screening different oligomers for cocrystallization, a 16 bp template (eta E) 
annealed to a 9 bp primer (eta E1) resulting in a 9 bp double strand with a sticky end of 
7 bases without an overlap at the template 3’ terminus led to a visually new crystal 
form with 0.2 M CaCl2 and 20 % w/v PEG 3350. These conditions were subsequently 
refined, however further optimization of the DNA length or sequence (Table 4-8) did 
not result in better crystals. 
5.4.2 Crystallizations with lesion containing DNA and ddCTP 
With a DNA sequence at hand which crystallized, a cisplatin lesioned oligonucleotide 
with the same sequence was prepared as described in 4.2.1.1 and crystallization setups 
were performed. 
The crystals of the Pol η – dsDNA - ddCTP complex were obtained overnight at 18 °C 
using the hanging-drop vapour diffusion technique (Figure 5-8 A). Macroseeding had 
to be performed at least 3 times in order to obtain larger crystals, suitable for diffraction 
(Figure 5-8 B).  
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Figure 5-8. A: Photograph of a Pol η – dsDNA - ddCTP crystal illuminated with polarized light, which 
was obtained in reservoir solutions containing 200 mM CaCl2 and 20 % (w/v) PEG 3350. B: The crystal 
in this photograph was macro seeded at 291 K in a crystallization solution consisting of 170 mM CaCl2 
and 16% (w/v) PEG 3350 three times to obtain a final size of 50 x 50 x 200 µm. 
 
Cryocooling was achieved by soaking the crystals for 5-10 seconds in reservoir 
solution containing 15 % D(-)-2,3-butanediol and flash-freezing in liquid nitrogen. 
Crystals grown under these conditions diffracted to a limiting resolution of 3.3 Å and 
belong to space group P41212 with two protein-DNA complexes per asymmetric unit. 
 
5.4.3 Crystallizations with lesion containing DNA and dNTPs 
The first obtained structure showed the ddCTP positioned in a loosely bound 
conformation in the active site, hydrogen bonded to the templating base. Realizing the 
importance of the nucleotides 3’-hydroxy group for correct positioning in the active 
site, which in turn positions the DNA correctly inside the polymerase we crystallized 
the complex once more, but with a dNTP in stead of the ddNTP. To prevent nucleotidyl 
transfer, primer strands terminating at the 3’-end with a 2’,3’ dideoxy ribose were 
prepared by reverse DNA synthesis as described in 4.2.2.  
In order to obtain crystal structures of the 3’dG and the 5’dG elongation steps, the 
register of the lesion in the template strands was adjusted so that the crystallization 
occurs in each case with a 16 bp template containing a site specific cisplatin lesion 
annealed to a 9mer primer (eta Ep1 and eta Ep2 respectively, Figure 5-9). The 3’dG 
elongation step was crystallized with a dCTP, whereas for the 5’dG elongation step 
only crystals with dATP could be obtained. 
5 Results 
 
 65
 
 
 
Figure 5-9. DNA constructs for cocrystallizing Pol η in the 3’dG elongation (eta Ep1) and 5’dG 
elongation (eta Ep2) steps. 
 
The ternary complex was allowed to form by incubating 2.5 equivalents eta Ep1 or eta 
Ep2 (Table 4-10) with dNTP (1 mM), MgCl2 (5 mM) and protein (0.1 mM) at room 
temperature for 10 minutes. Crystals were obtained overnight at 18 °C using the 
hanging-drop vapour diffusion technique by mixing 1 μl of protein-DNA complex with 
1 μl reservoir solution containing 170 mM CaCl2 and 16% (w/v) PEG 3350. The 
resulting crystals were macro seeded at least 3 times. However, repetitive seeding was 
limited by microcrystals, attached to the core crystal, which as well increased in size 
and prevented the core crystal to grow bigger. Cryocooling, for avoiding radiation 
damage during data collection, was achieved as described in 5.4.2. The obtained 
crystals diffracted typically to 3.1 - 3.3 Å resolution at a synchrotron light source and 
belong to space group P41212. The crystals have two protein-DNA complexes per 
asymmetric unit, which have unit cell dimensions of a = b = 104.1 Å, c = 293.0 Å for 
the 3’dG elongation (obtained with eta Ep1) and a = b = 103.7 Å, c = 292.8 Å for the 
5’dG elongation (obtained with eta Ep2), and α = β = γ = 90°. 
 
5.5 Structure solution and refinement 
Data were collected from crystals of the yeast Pol η complex at 100 K. The crystals 
diffracted to a limiting resolution of 3.1 – 3.3 Å at the SLS and ESRF synchrotron 
facilities. Data were autoindexed, integrated and scaled with the XDS suite[191] and the 
phases were determined by molecular replacement method as described in 4.2.9. A 
picture of the diffraction pattern is shown below (Figure 5-10 A), and the data 
processing statistics are listed in chapter 7.2.  
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Figure 5-10. A: Diffraction pattern recorded at the Swiss Light Sourse (SLS) synchrotron beamline PX1. 
B: The Fo-Fc difference electron density shown in red after the initial molecular replacement with the Pol 
η apoenzyme[129], which was used as the model for replacement, depicted as a cartoon. 
 
The initial model built into the density obtained by the replacement (Figure 5-10 B) 
was rebuilt manually with Coot[196] and refined with CNS[197] iteratively.  The final 
model of the ddCTP structure (4.2.7.2) contains residues 1 – 509 of the polymerase. 28 
residues at the N terminus, corresponding to the strep-tag and a linker, and 23 residues 
at the C terminus are missing in the electron density map. In the structures obtained 
with dNTPs (4.2.7.3), two more residues at the N terminus are visible in the electron 
density. The 5 bases of the overhang at the 5’ end of the template are missing in the 
electron density of all structures. For more details of the refined models see chapter 7.2. 
 
5.6 Crystal contacts 
Interestingly the Pol η ternary complex crystallized in the same space group as the 
apoenzyme (P41212) with very similar unit cell constants. The exact length of the DNA 
is crucial for obtaining crystals of the ternary complex as was realized from screeing 
experiments (4.2.7.1). The bound DNA is making tail to tail contacts with DNA 
belonging to another molecule (Figure 5-11).  
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Figure 5-11. Tail to tail DNA-DNA contacts contributing to the crystal packing.  
 
The resulting structure resembles a DNA encaged by 2 polymerases (Figure 5-12). The 
importance for the ideal length can now be derived from the obtained structures, 
wherein intermolecular DNA - DNA contacts contribute to the crystal packing. 
 
 
 
Figure 5-12. A: The two polymerases on the left side belong to the same asymmetric unit and are related 
through non crystallographic symmetry.  B: The polymerases shown on top as a surface model are 
omitted for clarity. The DNA is shown in sand colored cartoon and the incoming dNTP is shown in cyan. 
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5.7 Crystal structure of the Pol η ternary complex with ddNTP 
We realized after solving the structure, comprised of the polymerase, a cisplatin lesion 
containg template, a natural primer and a 2’,3’-didesoxycytidinetriphosphate that the 
ddCTP is not orientationed correctly in the active site. Although the triphosphate is 
complexed to the two metal ions, the sugar protrudes into the DNA binding cleft and is 
not aligned with Phe35 as expected (Figure 5-13). However, the ddCTP still establishes 
hydrogen bonds to the templating cisplatin lesion containing 3’dG via Watson - Crick 
base pairing. 
 
 
 
Figure 5-13. Close up view of the catalytic center. The enzyme is depicted as a cartoon with the catalytic 
residues shown as sticks. The Watson-Crick H-bonded ddCTP and the lesion containing bases are 
depicted as sticks. The two catalytic ions are shown as grey spheres. 
 
The 3’-OH group of the dCTPs ribose unit would control the positioning of the 
incoming nucleotide in the wide active site to establish a correct set of H-bonds with 
the lesion containing base. In the obtained structure the complex is inactive. The primer 
3’-OH group is 6 Å away from the dCTP α phosphate and thus unable to perform the 
nucleophilic attack. 
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5.8 Crystal structure of the Pol η ternary complex with ddprimer 
By crystallizing Pol η with eta Ep1 (with a dCTP) and eta Ep2 (with a dATP) we 
obtained crystal structures of the 3’dG and the 5’dG elongation steps opposite a Pt-GG 
lesion. The overall structure of Pol η resembles a right hand, similar to T7 DNA 
polymerase with palm, fingers, and thumb but with an additional structural element 
termed the "polymerase-associated domain," which is a four-β-sheet-structure with two 
α-helices.  
The palm, thumb and PAD form a DNA-binding groove that leads to the polymerase 
active site located within the palm domain. The orientation of the primer template 
places the primer 3’ end against the dNTP at the confluence of the fingers and palm 
(Figure 5-14).  
 
 
 
Figure 5-14. Overview of the Pol η structure in ternary complex with lesion containing DNA. The 
“3’dG elongation” complex is shown as a cartoon with the various domains of the protein color coded. 
In magenta, the cisplatin lesion is shown with the platinum anomalous electron density contoured at 10 
σ. The primer and template strands of the DNA (brown) and the Watson-Crick H-bonded dCTP 
(magenta) are depicted as sticks. The two catalytic magnesium ions are shown as grey spheres. 
 
By crystallizing Pol η together with the DNA template-primer construct eta Ep1 (Table 
4-10) in which the primer ends just before the Pt-GG lesion we obtained 2 structures, 
derived from the two different molecules of the asymmetric unit.  
The first structure shows the Pt-GG lesion in a situation before it enters the active site 
and wherein the Watson-Crick base pair with the incoming dCTP has not yet been 
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formed. This structure can be viewed as a “pre-elongation” form and will be described 
in 5.8.2. The second structure contains the Pt-GG lesion partially situated in the active 
site, with the 3’dG of the lesion forming a Watson-Crick base pair with the incoming 
dCTP. This complex represents a good model for the relatively efficient bypass of the 
3’dG of the lesion and will be described in more detail in 5.8.3.  
In order to get information about the replication through the 5’dG of the Pt-GG lesion, 
we crystallized Pol η together with the template-primer construct eta Ep2 (Table 4-10) 
in which the primer was designed to end just in front of the 5’dG base of the lesion. 
Again crystals were obtained, which provided two independent ternary complexes per 
asymmetric unit with a limiting resolution of 3.3 Å. In this case, the obtained structures 
are quite alike and will be described in 5.8.4. 
The Pt-GG crosslink is in all complexes well defined in the electron density and the 
bases forming the Pt-GG lesion are positioned in an appr. 90° angle with respect to 
each other. 
 
5.8.1 The catalytic center 
The catalytic center contains three strictly conserved and functionally important acidic 
residues consisting of Asp30, Asp155 and Glu156, which hold two metals in the active 
site. In the active polymerase these would be two Mg+2 cations, but in our structures the 
metals are presumably Ca+2 cations originating from the crystallization conditions. 
These metals in turn ligate the phosphates of the bound dCTP (Figure 5-15). The 
fingers are making numerous interactions with the bound nucleotide and in addition 
wall off this end of the DNA-binding groove. The DNA primer 3’ end is located in the 
joint between palm and fingers. The dCTPs 3’ hydroxyl group is interacting with the 
peptide backbone of Phe35 whilst the dCTPs’ ribose unit is interacting with the phenyl 
sidechain of Phe35. This residue is prohibiting ribonucleoside triphosphates from 
entering the active site because of unfavorable steric interaction with the 2'-OH and is 
termed the “steric gate”[201]. The catalytic residue Arg73, which is highly conserved in 
Pol η, interacts through electrostatic attraction of the side chain nitrogens with 
unesterified oxygens of the α and β phosphates and the esterified oxygen linking 
between them. In addition, the guanidinium group stacks on top of the base moiety of 
the incoming dNTP to establish a cation-π interaction [202]. 
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Figure 5-15. Detailed stereo view of the interaction of the dCTP with the surrounding at the 3’dG 
elongation status of the protein-DNA complex. Important is the H-bond between the 3’-OH and the 
protein backbone, which orients the dNTP in the binding pocket. 
 
All these interactions contribute to the correct positioning of the incoming dNTP in the 
active site, positioning it in anticipation of the subsequent 3’-OH nucleophilic attack.  
5.8.2 The 3’dG pre-elongation step 
In the pre-elongation complex, the Pt-GG lesion is positioned outside the active site 
and the 3’dG of the lesion is held at a rather large distance from the dCTP of about 6 Å 
(3’dG-O6•••4NH2-dCTP). Still, the dCTP is already positioned in the active site even 
in the absence of any templating base and complexed by two metal ions. These in turn 
are coordinated by the catalytically essential residues Asp30, Asp155 and Glu156 
(Figure 5-16 A). In this state, the expected 3’-OH group (absent in our structure due to 
the dideoxy terminus) of the primer is located about 8.5 Å away from the α-phosphate 
of the dCTP and hence unable to perform the primer elongation. The primer - template 
is held in position on one side of the DNA binding cleft by interactions of the fingers 
and the PAD, over a strech of 4 bases, with the templating strand. These interactions 
are 2 bases away from the templating 3’dG into the 3’ direction. On the other side of 
the DNA binding cleft, the thumb is making interactions primarily to the 
phosphodiester backbone of two bases, which are located 3 bases away from the 
incoming dCTP (Figure 5-16 B). 
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Figure 5-16. A: Active site of the “pre-elongation” complex. The catalytic residues together with the 
Ca+2 ions tightly bind the dCTP. Phe35 is placed upon the deoxyribose of the dNTP. The backbone 
carbonyl of Phe35 establishes a H-bond to the 3’-OH of the dNTP. Arg73 orients the nucleotide, which is 
still unpaired for H-bonding based recognition. B: Schematics of protein-DNA contacts. The primer-
template DNA is represented as a ladder, with the bases represented as rectangles, and the phosphates as 
circles. Direct hydrogen-bond contacts are indicated by solid lines between the amino acid name 
(coloured as in Figure 5-14) and a circle for phosphate contacts. DNA contacts with the symmetry-
related molecule are not shown. 
 
5.8.3 The 3’dG elongation step 
The 3’dG of the lesion establishes a perfect Watson-Crick base pair with the pre-
orientated dCTP (Figure 5-17 A). The side chain of Met74 of yeast Pol η has slipped 
into the π-surface notch (S-π distances of 3.8 Å) created by the two dG bases of the Pt-
GG lesion to create attractive S-π interactions[202]. Arg73 coordinates the dCTPs α- and 
β-phosphate and stacks with its base moiety. The distance between the putative 3’-OH 
nucleophile of the primer and the α-phosphate of the dCTP are reduced to only about 
5.0 Å, placing the dCTP ready for nucleotidyl transfer. Correct positioning of the dCTP 
for the 3’dG translesion synthesis step is guided by a H-bond between the 3’-OH group 
of dCTP and the backbone of Pol η at Phe35, as well as by hydrophobic interactions of 
the dCTPs’ ribose subunit with the phenyl ring of Phe35. The primer - template is held 
in position on one side of the DNA binding cleft by interactions of the fingers, palm 
and the PAD, over a strech of 3 bases, with the templating strand. These interactions 
are one base away from the templating 3’dG. On the other side of the DNA binding 
cleft, the thumb is making interactions primarily to the phosphodiester backbone of two 
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bases, which are located one base away from the incoming dCTP. The PAD is making 
a single interaction with the primer, one base from the 5’ end (Figure 5-17 B). 
 
 
 
Figure 5-17. A: The catalytic residues together with the Ca2+ ions tightly bind the dCTP. R73 orients the 
nucleotide for H-bonding based recognition. The dCTP pairs perfectly with the 3’desoxyguanine of the 
lesion. Met74 stacks in the hydrophobic π-notch between the two cisplatin complexing guanines. B: 
Schematics of protein-DNA contacts. The primer-template DNA is represented as a ladder, with the 
bases represented as rectangles, and the phosphates as circles. Direct hydrogen-bond contacts are 
indicated by solid lines between the amino acid name (coloured as in Figure 5-14) and a circle for 
phosphate contacts. DNA contacts with the symmetry-related molecule are not shown. 
 
5.8.4 The 5’dG elongation step 
The DNA duplex and the position of the putative 3’-OH of the primer, are arranged in 
an intermediary conformation compared to the “pre-elongation” and “3’dG elongation” 
complexes described before (Figures 5-16 and 5-17). The 3’dG of the lesion remains 
stably bound via a Watson-Crick base pair to the primer dC base. The incoming dATP 
stacks on top of the newly formed base pair. The 5’dG of the lesion has moved into the 
active site but the crosslinking Pt-bond to the 3’-dG forces this base to stay 
perpendicular relative to the incoming dATP and to the 3’dG-dC base pair as shown in 
Figure 5-18. Only one H-bond is established between the exocyclic C(6)-NH2 amino 
group of dATP and the C(6)=O carbonyl oxygen of the 5’dG. In this structure, the 
expected position of the primer 3’-OH is with 7.5 Å distance to the dATP larger as in 
the first elongation complex (5 Å) providing a rational for the slower second bypass 
step. 
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Figure 5-18. A: Active site of the “5’dG elongation” complex of Pol η. The catalytic residues together 
with the Ca2+ ions tightly bind the dATP. The nucleotide, ready for H-bonding based recognition, pairs 
with the lesions 5’desoxyguanine through only one hydrogen bond. B: Schematics of protein-DNA 
contacts. The primer-template DNA is represented as a ladder, with the bases represented as rectangles, 
and the phosphates as circles. Direct hydrogen-bond contacts are indicated by solid lines between the 
amino acid name (coloured as in Figure 5-14) and a circle for phosphate contacts. DNA contacts with the 
symmetry-related molecule are not shown. 
 
The primer - template is held in position on one side of the DNA binding cleft by 
interactions of the fingers and the PAD, over a strech of 5 bases, with the templating 
strand. On the other side of the DNA binding cleft, the palm is interacting with the 
phosphate backbone 5’ of the incoming dCTP. The thumb is making interactions to the 
following 2 bases and also the PAD contacts the primers’ phosphate backbone at the 
last two bases (Figure 5-18 B). 
 
 
 
Figure 5-19. A: Overview of complex 2 of the 5’dG elongation step. B: The catalytic residues together 
with the Ca2+ ions bind and preorient the dATP in the active site. However, there is a large distance 
between the α-phosphate of the dNTP and the putative primer OH in the absence of the H-bond between 
the dNTP and the 5’desoxyguanine. 
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In complex 2 of this step, the 5’dG is with a 9.5 Å distance to the α-phosphate even 
larger and no hydrogen bond is formed to the dATP (Figure 5-19).  Thus, the single H-
bond formed between the two perpendicularly oriented heterocycles pulls the primer 
strand and the dATP together rationalizing the “slow” nucleophilic attack of the α-
phosphate for primer extension. Such a H-bond is besides with dATP only possible 
with dCTP via the C(4)-NH2 amino group, explaining why these two nucleotides are 
preferentially inserted opposite the 5’dG by the yeast Pol η during the second step of 
lesion bypass (5.9.1). 
 
5.8.5 The polymerase-associated domain  
The DNA binding surface area enclosed by the palm, fingers, and thumb domains in 
Pol η  is with 675 Å2 substantially less than in T7 Pol with 1630 Å2. The size of the 
Pol η hand is augmented by an extra domain, the PAD consisting of residues 393–508. 
The PAD is joined to the thumb through a flexible linker that traverses the DNA 
binding groove from the thumb to the fingers side and has resemblance to the palm in 
containing a mixed β sheet and two long α helices. The two β sheets are roughly 
perpendicular to each other, and are the principal elements defining the floor and the 
wall of the DNA binding cleft (Figure 5-20).  
 
 
 
 
Figure 5-20. Overlay of the 3’dG elongation (colour coded as in Figure 5-14) and the the 3’dG pre-
elongation (grey) complexes depicted as comics. The two views are related by a 90° rotation around a 
horizontal axis. The bound DNA is omitted for clarity. 
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Most importantly, the inclusion of the PAD increases the potential DNA binding 
surface of Pol η from 675 Å2 to 1113 Å2, which is comparable to that observed in other 
DNA polymerases. 
The reorientation of the DNA from the pre-elongation into the 3’dG elongation state is 
accompanied by small motions of the thumb and PAD domains, relative to the palm 
and finger domains (Figure 5-20). The PAD is moving towards the DNA, performing a 
slight closing motion, whilst the thumb is moving as well and establishes more contacts 
to the DNA in proximity of the catalytic center (Figures 5-16 B and 5-17 B). These 
movements induce a shift of the DNA contacts relative to the PAD domain by one base 
pair (Figure 5-21). 
 
 
 
Figure 5-21. View of the DNA in proximity of the PAD domain. Overlay of the Pol η PAD domains 
of the 3’dG elongation state (colour coded as in Figure 5-15 with the DNA in magenta) and the the pre-
insertion state (grey with the DNA in cyan). Peptide residues making functional contacts to the DNA are 
depicted as sticks with the carbon atoms shown in the colour of the corresponding peptide.  
  
Comparing the 3’dG pre-elongation  with the 3’dG elongation complex, using a 
different distance matrix plot[203], shows that relatively few changes occur within the 
individual domains, whilst marked shifts occur in the domains’ positions relative to 
each other (Figure 5-22). 
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Figure 5-22. The difference distance matrix of the Pol η insertion complex was subtracted from the 
difference distance matrix of the Pol η pre-insertion complex. The delta values are plotted with colors 
representing CA differences of -3.0 to 3.0 Angstroms according to the scale at the top. 
 
The areas that are essentially white (palm and fingers) represent regions of close 
structural similarity, without significant movement. The colors are interpreted to mean 
that the PAD domain of the 3’dG elongation complex is closer (red) to the center of 
mass than the same domain of the 3’dG pre-elongation structure. In contrast, the thumb 
domain of the 3’dG elongation complex is farther away (blue) from the center of mass 
than the corresponding domain in the 3’dG pre-elongation complex. 
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5.9 Biochemical studies 
The primer extension studies were planned together with Claudia Chioccini, who 
carried them out. The reaction conditions are given in the legends. 
5.9.1 Nucleotide insertion studies 
The specificity of translesion synthesis opposite the damaged (lesion) and undamaged 
(native) bases was evaluated by using GG_comp1 for studying the incorporation 
opposite the 3’dG (Figure 5-23 A) and GG_comp2 for studying the incorporation 
opposite the 5’dG (Figure 5-23 B). Template strand DPO4_GG (Table 4-9) was 
prepared as described in 4.2.1.1 and purified by HPLC as described in 4.2.2. The 
template strand was annealed to the 5’ fluorescein labeled primer strands GG_comp1/2 
in the reaction buffer in a 1:1.5 ratio in order to ensure that all primer strands anneal.  
 
 
 
Figure 5-23. The reactions were carried out using 150nM Pol η, 1µM DNA, 500µM dNTPs and 
incubating at 35°C for 30 minutes. The markers (M) represent an insertion opposite the 3’dG (14mer) 
and the 5’dG (15mer). The dNTP used in each experiment is noted at the top of the lanes. A: Nucleotide 
insertion studies opposite the 3’guanine. B: Nucleotide insertion studies opposite the 5’ guanine.  
 
Primer extension studies revealed that Pol η inserts opposite the lesioned 3’dG mainly 
a dCTP and in the absence of the lesion besides the preferential incorporation of dCTP 
also a dTTP. In both cases the bypass is highly efficient and mostly error free 
(Figure 5-23 A). 
Opposite the lesioned 5’dG the bypass is much slower and promiscuous for dCTP and 
dATP, whereas for the unlesioned template mainly dCTP and to a lesser extend a dTTP 
insertion is observed (Figure 5-23 B).  
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5.9.2 Structure based point mutation of Arg73 
To gain further insight into the biochemistry of the bypass reaction we analyzed a site 
directed mutant of Pol η. We noticed that the Arg73 residue seems to activate and 
stabilize the dNTP for the lesion bypass steps, from the side opposite of the two metal 
ions. Interestingly, Arg73 is highly conserved among Pol η homologs, but not among 
other Y-family polymerases (Figure 5-24). This raises the question how much this 
residue determines the efficiency of the lesion bypass process.  
 
 
 
Figure 5-24. A. Sequence alignment of S. cerevisae, human and mouse Pol η, DPO4 and human Pol ι 
showing that R73 is conserved in Pol η homologs, but not in other Y-family polymerases. Secondary 
structure elements are depicted as rectangle for α helix and arrow for β strand. B: Structural alignment of 
the yeast Pol η, human Pol ι and DPO4 shows that Arg73 of Pol eta is in the Pol iota structure close to a 
Leu residue. By sequence alignment it occupies the same position as a Lysine residue. DPO4 possesses 
at that position an Ala. 
 
A mutant of Pol η, wherein Arg73 was mutated to leucine (η*) was kindly prepared 
and provided by Carsten J. Pieck. This mutant also consisted of 532 amino acids, 
analogous to the unmutated polymerase. 
The efficiency of translesion synthesis opposite undamaged and the damaged bases was 
evaluated by using eta_Ep1 with and without a site specific cisplatin lesion for primer 
extension studies. 
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Figure 5-25. Reactions were carried out with 1μM DNA substrate, 250nM Pol η, and 200μM dNTPs at 
26C° for the indicated amount of time. The markers (M) represent an insertion opposite the 3’dG 
(10mer), the 5’dG (11mer) and a full extension (16mer). A: Time dependent primer extension studies 
with Pol η (η) and Pol ηR73L (η*) using eta Ep1 but without the site specific cisplatin lesion. B: Time 
dependent primer extension studies with Pol η (η) and Pol ηR73L (η*) using eta Ep1 containing the site 
specific cisplatin lesion. 
 
We found that Pol η* still can replicate undamaged templates, although the 
polymerization efficiency is substantially reduced when compared to the unmutated 
polymerase (Figure 5-25 A). Opposite a Pt-GG lesion, Pol η* is able to perform the 
first bypass step opposite the 3’dG slowly, in comparison with the wild-type enzyme, 
whereas the second step of lesion bypass, opposite the 5’dG is strongly compromised 
(Figure 5-25 B). The same biochemical properties are observed with CPD lesions 
(Figure 5-26), showing that the function of R73 is generally required for the replication 
through intrastrand cross-links. 
 
 
 
Figure 5-26. Primer extension experiment with Pol η and Pol ηR73L (η*) across a cyclobutane 
pyrimidine dimer (CPD) and undamaged DNA (U).  The first two lanes contain markers for the 
unelongated primer (9mer) and the full extension product (16mer). Reactions were carried out using 
250nM Pol η/Pol ηR73L, 1µM template DNA (eta Ett1), 200µM dNTPs and incubating at 26°C for 3h.  
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5.9.3 Functional hydrogen bonding studies with Zebularine 
Primer extension studies were performed with Pt-GG containing templates and the 
5’-triphosphate of 6-deaminocytidine (zebularine, dZTP), which was kindly prepared 
and provided by David Kuch. This base analog of cytidine, lacking the exocyclic C(4)-
NH2 amino group, can not form the H-bond to the C(6)=O carbonyl oxygen of the 
5’dG, but can still form the two other H-bonds to dG.  
 
 
 
 
Figure 5-27. Efficiency of the translesion synthesis past the 3’dG and the 5’dG of the Pt-GG lesion. 
Reactions were carried out by incubating Pol η at increasing concentrations (lanes 1-7: 
20/40/80/120/160/200/300 nM) for 20 minutes at 30°C with 500µM dCTP (A and B) or 500µM dZTP 
(C) and 1µM template DNA. A 13mer (A) or 14mer (B and C) hybridized to a 18mer DNA template 
(DPO4_GG) containing a site specific cisplatin lesion was used. The fluorescein labeled 14mer was used 
as a marker (M). 
 
The translesion synthesis exhibited by Pol η past the 3’dG of the Pt-GG lesion is very 
efficient (Figure 5-27 A). Bypass past the 5’dG of the Pt-GG lesion with dCTP is 
slower than the preceding step (Figure 5-27 B) and is even more dramatically reduced 
when dZTP is being incorporated (Figure 5-27 C). 
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5.10 Cloning, expression and purification of DNA Pol η-513  
The S. cerevisiae Rad30 gene encodes the 632 residues of full length Pol η. A 
shortened, active version of 532 amino acids, truncated at the C-terminus was cloned 
and purified originally in our laboratory for primer extension experiments[188, 189].  
For crystallization optimization we were in need of a slightly shortened version of the 
already shortened version at hand. These missing C terminal residues of the yeast Pol η 
catalytic core are of regulatory use, but do not affect the catalytic properties of the 
DNA polymerase and its translesion synthesis properties. They extend from the 
polymerase-associated domain and in vivo interact with the host replication complex, 
which targets Pol η to the replication fork through an interaction between PCNA[204] 
and residues 621–628 near the Pol η C-terminus [205]. 
 
A PCR product encoding Pol η 513 fused to a strep-tag was amplified by using the 
expression vector pDEST007-polη as a template and the primers Rad30-Gate-N and 
Pol η-513_R (Table 4-11). The expression clone was inserted by BP reaction into the 
entry clone, which was then subcloned in pExp007 by LR reaction. Both reactions are 
based on the Gateway technology. The resulting vector was transferred in E. coli 
Rosetta-gami and expression was performed identical to the protocol established by Dr. 
Claudia Chioccini (Figure 5-28).  
 
 
 
Figure 5-28. Expression and purification of Pol η-513. From left to right: cells before induction, cells 
after 4 hours induction, cell residues after lysis, cell lysate after lysis, Strep-tag purification, heparin 
purification and marker. 
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Pol η 513 was purified on a Strep-Tactin Superflow column identical to the protocol 
established by Dr. Claudia Chioccini. Thereafter the buffer was exchanged to Heparin 
buffer A and the protein was passed over a HiTrap™ Heparin HP ion exchange column 
for removing remaining DNA (Figures 5-28 and 5-29). 
 
  
Figure 5-29. Elution profiles of Pol η-513 (absorption at 280 nm in blue; absorption at 254 nm in red) 
from a Strep-Tactin Superflow cartridge (left) and from a HiTrap™ Heparin HP Column (right). 
 
After pooling and concentrating the fractions of the eluted protein, the concentration 
was determined on a BioPhotometer 6131. 
 
5.11 RNA Pol II stalling at a cisplatin lesion 
The detailed molecular mechanisms of cisplatin DNA adduct processing by nucleic 
acid polymerases are not understood. In order to derive the molecular mechanism of 
S. cerevisiae RNAP II stalling at cisplatin lesions, the DNA templates Pol2_GG, 
Pol2_CGG and Pol2_IG (Table 4-10) were prepared as described in 4.2.1.1 for a 
collaboration with the group of Prof. Cramer. These oligomers contained a site specific 
lesion at a GG or an IG sequence and were used in a combination of X-ray 
crystallography and RNA-extension assays by the Cramer group to elucidate 
recognition of cisplatin-induced DNA damage by transcribing RNAP II. Elongation 
complexes for crystallization were reconstituted from the 12-subunit S. cerevisiae 
RNAP II and the nucleic acid scaffolds as described[206, 207]. For this, the strands were 
planned with a cisplatin lesion incorporated at registers +2/+3 of the template strand, 
directly downstream of the NTP-binding site at register +1 (Figure 5-30).  
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Figure 5-30. Nucleic acid scaffold. Filled circles denote nucleotides with interpretable electron density 
that were included in the structure (Figure 5-31); open circles denote nucleotides with uninterpretable or 
absent electron density. 
 
The obtained crystal structure of the resulting cisplatin-damaged elongation complex 
was determined at 3.8 Å resolution. A very strong peak in the anomalous difference 
Fourier map revealed the location of the platinum atom, which was used as a marker 
for lesions positioning and determination of the register (Figure 5-31). 
 
 
 
Figure 5-31. Structure of nucleic acids in RNAP II elongation complex A. Final 2Fo-Fc electron density 
map for the nucleic acids is shown (blue, contoured at 1.0 ). Anomalous difference Fourier map reveals 
the location of the platinum atom (magenta, contoured at 15σ). 
 
In the damaged elongation complex structure, the cisplatin lesion is bound at positions 
+2/+3, above the polymerase bridge helix (Figure 5-32).  
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Figure 5-32. Overview of the cisplatin-damaged RNAP II elongation complex. RNAP II is shown as a 
silver ribbon, with the bridge helix highlighted in green. The nucleic acids are in color, and the cisplatin 
lesion is shown as a stick model in orange. A large portion of RNAP II was omitted for clarity. 
 
The DNA-RNA hybrid occupies the upstream positions -1 to -8 (Figure 5-30). The 
hybrid structure is essentially identical to previous structures of the complete RNAP II 
elongation complex[207] and the elongation complex containing a CPD lesion at the 
polymerase active site[206]. However, the downstream DNA duplex adopts a slightly 
altered position (Figure 5-33).  
 
 
 
Figure 5-33. Cisplatin-induced changes in the downstream DNA. Comparison of the course of nucleic 
acids in the structures of the cisplatin-containing (pale green) with the CPD-containing complexes (violet 
and light blue). The proteins were superimposed on the basis of the active site region and then omitted. 
Nucleic acids are depicted as ribbons, lesions as orange sticks. 
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The change in the downstream DNA position results from the presence of the cisplatin 
lesion rather than from the scaffold design or the nucleic acid sequences, which were 
highly similar to those used previously and differed only in the substitution of Gs by 
Cs[206]. This was done in order to obtain a selective platination of the template strand 
and avoid unwanted side products. Structures of short DNA oligomers containing a 
cisplatin lesion reveal that the lesion at the center of the duplex leads to DNA bending 
(Figure 3-5)[65, 208]. In our structure, the lesion is located at the end of the duplex and 
induces a slight repositioning of the downstream DNA, without substantial changes in 
its internal structure. 
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6 Discussion 
6.1 Lesion bypass 
6.1.1 Lesion bypass of a 1,3-d(GpTpG) oxaliplatin lesion 
Pol η was shown to bypass a 1,3 GTG oxaliplatin in vitro by inserting to a high degree 
the correct nucleotides (Figures 5-4 and 5-5). The lesion bypass seems to be slower 
than the bypass of an undamaged strand based on the gels which show still unelongated 
primers for the lesion containing strands. However kinetics need to be measured for the 
bypass of this lesion with Pol η to make a quantitive statement.  
Solution structures of a double stranded DNA with a site specific 1,3 GTG cisplatin 
lesion show the T positioned in the minor groove and stacking with the 5’G. The T also 
does not hydrogen bond with its complimentary A, which stacks with its flanking Cs as 
in B-DNA (Figure 3-5)[66]. This could lead to the suggestion that Pol η inserts an A 
opposite the T in a non instructive fashion, a mechanism called A-rule[209, 210]. 
However, Pol η does not insert an A opposite an abasic site but a G, and this only in a 
very inefficient manner[161]. This led to the suggestion that Pol η does not follow the 
A-rule[210]. Pol η also requires instructions, based on hydrogen bonding, for inserting 
efficiently a complementary base[166].  Therefore it seems that the T, flanked by the two 
Gs of the lesion, is bypassed in an instructive fashion, rather than by following the A-
rule.  
One could argue that the whole lesion is flipped out of the active site and the next base, 
which is also a T, is responsible for instructing the insertion of an A. This could be 
easily investigated by conducting an experiment wherein a template strand containing 
the 1,3 GCG lesion is used for the primer extension experiments. 
In summary, it seems that the active site of Pol η is big enough to accommodate the 
1,3-GTG oxaliplatin lesion and that this lesion is processed in an efficient and 
instructive fashion.  
6.1.2 Lesion bypass of a 1,2-d(GpG) cisplatin lesion 
The structures of the ternary complex of yeast Pol η with a Pt-GG in the template DNA 
and an incoming dNTP have provided clear evidence that its active site is open enough 
to accommodate both residues of a Pt-GG (Figures 6-1 and 6-2). This is in contrast to 
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most DNA polymerases, which include not only the high-fidelity replicative 
polymerases but also the other members of the Y-family, in which only the templating 
residue can fit in the active site, whereas the next 5'-template base along with the rest of 
the unpaired template is pushed out of the active site at a 90° angle [100-102, 106-109, 211-213]. 
Because the two purines of a Pt-GG are covalently linked by the cisplatin and therefore 
cannot be separated, the active site of most polymerases is not equipped to handle this 
lesion. Interestingly, at the 3’dG elongation step, the base 5’ to the templating base is in 
a nearly 90° angle to the base located in the active site due to the conformation induced 
by the cisplatin crosslink. This highly resembles the conformation adapted by the 
unpaired template strand in high-fidelity replicative polymerases (Figure 3-9). 
 
 
Figure 6-1. Protein surface representation of Pol η with the DNA and dNTP depicted as sticks, showing 
the 3’dG elongation step. The primer is yellow and the dNTP to be inserted is red. The template strand is 
blue, with the templating nucleotide in olive and the nucleotide to its 5′-side in brown. The magnesium 
ions are depicted as grey spheres. 
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Figure 6-2. Protein surface representation of Pol η with the DNA and dNTP depicted as sticks, showing 
the 5’dG elongation step. The primer is yellow and the dNTP to be inserted is red. The template strand is 
blue, with the templating nucleotide in olive. The magnesium ions are depicted as grey spheres. 
 
The four obtained Pol η complexes plus the biochemical data allow us to suggest a 
plausible scenario of how Pol η manages to bypass Pt-GG lesions.  
 
 
 
Figure 6-3. The 3’dG elongation process of Pol η. A: Detailed view of the lesion in the “pre-
elongation” complex (cyan) superpositioned with the lesion in the “3’dG elongation” state (magenta). 
B: Correct Watson-Crick base pairing revolves the DNA to position the 3’-OH of the primer for 
nucleophilic attack on the α-phosphate of the dNTP. For clarity the finger domain has been omitted and 
the DNA molecules (cyan and magenta) are viewed in a simplified form. 
 
The enzyme seems to bind the template-primer complex first in a non-productive 
manner described by the 3’dG pre-elongation state (Figure 6-3 A). The dNTPs are 
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bound and presumably rapidly exchanged in the active site in the absence of a 
templating base. If the templating base is able to establish a sufficient number of H-
bonds with the dNTP, it shifts the primer-template equilibrium toward the 3’dG 
elongation state, in which nucleotidyl transfer occurs (Figure 6-3 A).  This revolving 
motion (Figure 6-3 B) results in reorientation of the DNA from the 3’dG pre-elongation 
into the 3'dG elongation state and is accompanied by small motions of the thumb and 
PAD domains, relative to the palm and finger domains (Figure 5-20). The DNA 
contacts to the PAD are shifted by one base pair (Figure 5-21), which likely helps to 
maintain the contact between Pol η and the DNA template upon switching between 
both states.  
In the second step of lesion bypass, described by the 5’dG elongation complex,  the 
primer template moves forward, with one H-bond apparently being the minimum 
requirement to pull the template primer complex toward the incoming dNTP in order to 
allow the 5'dG nucleotidyl transfer, albeit at much reduced efficiency and accuracy. 
This scenario is supported by various biochemical observations[166, 214]. A rate 
determining conformational adjustment was determined by pre-steady state kinetic 
experiments. Although these data were obtained with undamaged DNA templates, such 
a process could be the revolving motion of the DNA-template complex, which is 
essential in order to bring the dNTP in close proximity to the 3’-OH of the primer. This 
conformational rearrangement was indeed found to precede the chemical step. [214] Such 
a step would be mechanistically quite distinct from the dNTP directed induced fit 
observed in high fidelity polymerases [100, 101] and could be a specific adaptation for 
replication of templates containing intrastrand crosslink lesions.  
Regardless, the structural mechanism of primer extension argues that Pol η selects 
correct dNTPs not by shape [215, 216] but by hydrogen bond complementarities, which is 
fully consistent with previous biochemical observations [166]. Pol η seems to share this 
property with the herpes simplex virus and human DNA primases, which both were 
shown to select the correct dNTP based exclusively on H-bonding complementarity[217, 
218]. 
To test this key hypothesis, we performed functional hydrogen bonding studies with Pt-
GG containing templates and the 5’-triphosphate of 6-deaminocytidine (dZTP). This 
base analog can not form the H-bond to the O(6) of dG.  
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As predicted from our structural model, bypass of the 5’dG with dZTP is dramatically 
reduced compared to bypass with dCTP or dATP (Figure 5-27), which verifies the 
essentiality of hydrogen bond formation for substrate recognition and incorporation by 
Pol η.    
 
6.2 Compare to the apoenzyme 
A comparison of the 3’dG elongation complex and the Pol η apoenzyme[129] reveals 
small but significant changes upon DNA binding. In particular, the whole thumb 
domain moves towards the DNA (Figure 6-4). The loop, formed by the residues 306-
312, contacts the DNA backbone and the loop 353-363 moves towards the minor 
groove. The β-sheet β14 of the PAD domain moves by about 4 Å towards the DNA 
backbone. 
 
 
 
Figure 6-4. Overlay of the apoenzyme with the first elongation complex The “3’dG elongation” 
complex is shown as a cartoon with the various domains of the protein color coded and superpositioned 
with the apoenzyme (1JIH)[129] in grey. In magenta, the cisplatin lesion and dCTP are shown. The primer 
and template strands of the DNA in brown and the Watson-Crick H-bonded dCTP in magenta are 
depicted as sticks. The two catalytic magnesium ions are shown as grey spheres. The views are related by 
a 90° rotation around a horizontal axis. 
 
Comparison of the apoenzyme with the 3’dG elongation complex, using a different 
distance matrix plot[203], shows that relatively few changes occur within the individual 
domains, whilst marked shifts occur in the domains’ positions relative to each other 
(Figure 6-5). One exception, clearly highlighted in the plot, is loop 73-74 consisting of 
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the structurally identified Arg73, which orients the dCTP in the active site and Met74, 
which slips in between the two cisplatin bound guanines.  
 
 
 
Figure 6-5. The difference distance matrix of the Pol η 3’dG elongation complex was subtracted from 
the difference distance matrix of the Pol η apoenzyme. The delta values are plotted with colors 
representing CA differences of -3.0 to 3.0 Angstroms according to the scale at the top. 
 
Those areas that are essentially white (palm and fingers) represent regions of close 
structural similarity. The colors are interpreted to mean that the PAD domain of the 
3’dG elongation complex is closer (red) to the center of mass than the same domain of 
the apoenzyme structure. In contrast, the thumb domain of the insertion complex is 
farther away (blue) from the center of mass than the corresponding domain in the 
apoenzyme structure (Figure 6-5).  
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6.3 Polymerase switch 
Studies with yeast Pol η and its natural substrate, the TT dimer, reveiled that the 
polymerase inserts a correct nucleotide opposite the 3’dT of the dimer, which results in 
its stable association with the TLS intermediate. The Pol η - DNA complex remains 
stable after the incorporation of nucleotides opposite the 5’dT of the dimer and the next 
two nucleotides beyond the lesion[219]. Thereafter, the Pol η - DNA complex is no 
longer stable, and Pol η dissociates from the DNA. In addition, DNA synthesis by Pol 
η up to two nucleotides beyond the TT dimer was shown to be both, necessary and 
sufficient to allow Pol α to resume DNA replication[220]. 
This implies that Pol η senses the location of the dimer as synthesis proceeds. By 
analyzing our structures with a Pt-GG one notices that termination following 
incorporation of 2 nucleotides beyond the cisplatin lesion places the two damaged bases 
at the third and fourth base pairs of the duplex primer template (Figure 6-6). This 
positions the lesion in immediate proximity of the PAD domain, which is present only 
in Y-family polymerases and differs among family members. 
 
 
 
Figure 6-6. Interaction of the template strand with the PAD. The structure presented is the 3’dG 
insertion complex, wherein the 3’dG of the Pt-GG is copied (position1). The insertion of another 3 bases 
would place the lesion in immediate proximity of the PAD (position 4). The primer strand is shown as a 
simplified cartoon for clarity. 
 
The reason for the lowered affinity of Pol η to the DNA at this point of replication 
could be explained by unfavourable interactions of the lesions phosphodiester 
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backbone with the PAD domain. Due to the two guanines rigid connection through the 
platinum, the backbone of the lesion itself is also less flexible than in undamaged DNA. 
This might result in clashing of the backbone into the PAD as replication after the 
lesion continues, rather than sliding along the PAD. This interaction might then result 
in disassociation of Pol η from DNA, which triggers the switch to another polymerase. 
Whether or not PCNA must be specifically deubiquitinated in vivo to facilitate such 
dissociation and further polymerase switches remains an open question. 
 
6.4 Use of ddNTP leads to potential misinterpretations of the 
structures 
To investigate the mechanism that allows Pol η to replicate through helix disturbing 
DNA lesions, we crystallized a 16-base-pair DNA template strand containing a single 
Pt-GG intrastrand crosslink, hybridized to a 9mer primer strand and a 
dideoxycytidinetriphosphate (ddCTP) in complex with the large fragment of DNA 
polymerase η from yeast. This resulted in the first crystal structure of this eukaryotic Y-
family polymerase in ternary complex.  
However we realized that by using a natural primer and a ddCTP, which was used to 
inhibit nucleotidyl transfer, we obtained a structure wherein the ddCTP is not placed 
correctly in the active pocket for base pairing. Although the triphosphate stays 
complexed to the two metal ions and Arg73 residue coordinates the ddCTPs’ 
phosphates from the side opposite of the two metals, the sugar triphosphate unit adopts 
a stretched out conformation, with the base protruding into the DNA binding cleft 
(Figure 6-7).  
Since Pol η contains a wide DNA binding cleft and the DNA can slide along the PAD 
with some degree of freedom, the template adjusted itself to the location of the ddCTP 
and established bona fide Watson-Crick hydrogen bonding. This also resulted in the 
lesion being located outside the active pocket. 
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Figure 6-7. Overlays of Pol η,crystallized with a ddCTP (grey) with the Polη 3’dG elongation state 
(green and magenta), which was crystallized with a dCTP. The catalytic carboxylates, Ca+2 ions, lesions 
and the incoming nucleotide are shown in the stick model. The overlays were generated by 
superimposing the palm domains of the two proteins. 
 
We postulated that by using a 2’-deoxycytidinetriphosphate (dCTP) for the 
crystallization setup, we would obtain a structure, wherein the dCTP would be confined 
to the active site by interactions of the 3’hydroxyl group with the peptide backbone of 
Phe35. The 3’-OH group would control the positioning of the incoming nucleotide in 
the wide active site to establish a correct set of H-bonds with the lesion containing 
base. Based on these structural results, obtained by cocrystallizations with ddCTP and 
the compare to the structures obtained by crystallizing with dCTP (Figure 6-7), we 
assume that parts of the reported discrepancies between biochemical[221] and 
structural[183] data of the translesion synthesis process of Y-family polymerases may be 
explainable with the use of dNTPs in the crystallization experiments. These will be 
discussed in further detail in chapter 6.5. 
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6.5 DPO4 vs Pol η lesion bypass 
Dpo4 from archael S. solfataricus is phylogenetically related to the DinB group of 
Y-family polymerases, members of which, like E. coli Pol IV and human Pol κ, are 
highly inefficient at replicating through CPDs[222]. Although Dpo4 can replicate 
through a cis-syn TT dimer, it does so with a much more reduced efficiency than does 
Pol η. However, it has been suggested that in its lesion bypass properties, including its 
ability to bypass CPDs, it is more akin to Pol η than to the other Y-family 
polymerases[223]. 
Dpo4 was used as the model polymerase for clarifying the TLS past TT dimers and was 
crystallized in ternary complex with ddATP and a TT dimer containing template–
primer DNA strand. The x-ray crystal structure of Dpo4 complexed with a cis-syn TT 
dimer has shown that, whereas the 3’dT of the CPD (TT-1) forms a Watson–Crick base 
pair with the incoming dideoxy ATP (Figure 6-8 A), the 5’dT (TT-2) forms a 
Hoogsteen base pair with the dideoxy ATP in syn conformation (Figure 6-8 B)[183].  
 
 
 
Figure 6-8. Overlays of DPO4 (grey with labels in black) with the Polη 3’dG elongation state (green and 
magenta with labels in magenta). A: DPO4 in ternary complex with a ddATP opposite the 3’dT of a TT 
dimer (TT-1). B: DPO4 in ternary complex with a ddATP opposite the 5’dT of a TT dimer coordinated 
via Hoogsteen base pairing (TT-2). The overlays of the TT-1 and TT-2 structures with Pol η were 
generated by superimposing the palm domains of the two proteins. 
 
Based upon these structures, a similar mechanism for nucleotide incorporation opposite 
a TT dimer has been proposed for Pol η. However biochemical studies with dNTP 
analogues showed that both Dpo4 and Pol η indeed do proceed by different 
mechanisms, but neither of them engage in Hoogsteen base pairing for incorporating an 
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A opposite the 5’dT of the CPD[221].  The mechanism of CPD bypass opposite the 3’dT 
adopted by Dpo4 resembles that used by T7, in which nucleotide incorporation involves 
an abasic site-like intermediate[130], whereas Pol η uses the normal Watson–Crick base 
pairing[221]. Opposite the 5’dT both polymerases incorporate an A by using Watson-
Crick base pairing. 
The origin of the misinterpretation of the DPO4 crystal structures in ternary complex 
with a TT dimer might lie in the use of a ddATP, which lacks the 3’ hydroxyl group, 
vital for correctly positioning the triphosphate in the polymerases’ active pocket. When 
superimposing the structures of DPO4 with our structure obtained for the 3’ elongation 
step one can clearly see the similarities to our structure which was obtained by 
cocrystallization with a ddCTP (Figure 6-7). The three catalytic carboxylates Asp7, 
Asp105 and Glu106 of DPO4 are superimposable with Asp30, Asp155 and Glu156 in 
Pol η for both complexes TT-1 and TT-2 as are Tyr12 and Phe35 which comprise the 
steric gate (Figure 6-8). In both DPO4 structures the ddATP protrudes out of the active 
site establishing hydrogen bonds to the templating CPD, in the case of TT-2 via 
Hoogsteen base pairing.  As was observed for the TT-2 structure the templating 
thymine did not rotate 36° or rise by 3.4 Å relative to the preceding base pair as in 
normal DNA. The incoming ddATP assumed a syn conformation and formed a 
Hoogsteen base pair with the 5’ thymine of the CPD and thereby maintained the 
triphosphate contact with Dpo4 for nucleotidyl transfer. 
According to the biochemical observations in the case of TT-1 the templating CPD can 
not enter the active site. This is actually observed in the crystal structure, but the base 
pairing is still maintained since the ddATP is not confined to the active site due to the 
lack of the 3’ hydroxyl group, which would establish a hydrogen bond to the backbone 
of Tyr12. Because of the same reason the TT-2 structure reveals a Hoogsteen base 
pairing. The ddATP is in a stretched out conformation and the template is in position 
for replication. Would the ddATP pair through Watson-Crick hydrogen bonds in this 
structure, the DNA would need to be pushed away from the active site. This way the 
DNA is correctly positioned, however the ddATP needs to adapt a syn conformation 
and thus Hoogsteen base pairing was observed for this structure. 
Polymerases belonging to the Y-family are characterized by more open and relaxed 
active sites and thus the correct positioning of the dNTP in the active site is of higher 
6 Discussion 
 
 98
importance than in high fidelity polymerases. These rely on an induced fit mechanism 
and therefore the absence of the 3’ hydroxyl group is of lesser importance.  
Parts of the reported discrepancies between biochemical[221] and structural[183] data of 
the translesion synthesis process of Y-family polymerases may be explainable with the 
use of dNTPs in the crystallization experiments, which should be employed in 
crystallizations of polymerases belonging to the Y-family. 
 
6.6 Mechanism of transcriptional stalling at cisplatin lesioned DNA 
6.6.1 RNA polymerase II stalling and AMP misincorporation 
The crystal structure of complex A which was crystallized with scaffold A (Figure 6-9) 
defines a state of the elongation complex in which the lesion lies downstream of the 
active site (Figures 5-31 and 5-32). Complex A was therefore used in RNA-extension 
assays to investigate the mechanism of RNAP II stalling.  
 
 
 
 
Figure 6-9. Nucleic acid scaffolds for crystallizations and primer extension studies.  
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Most of the RNA was extended by two nucleotides (Figure 6-10). Thus, the complex 
apparently stalled after nucleotide incorporation opposite the first guanosine (the 
3'-guanosine) of the cisplatin lesion. Incubation of complex A with subsets of NTPs 
suggested that the terminal incorporation is a specific misincorporation of AMP 
(Scaffold A, Figure 6-10).  
 
 
 
Figure 6-10. RNA extension with scaffolds A and B. Lanes 1 and 7 show the fluorescently labeled 
reactant RNA. In the other lanes, the scaffolds were incubated with RNAP II and indicated NTPs (1 mM) 
for 20 min. 
 
To further investigate this, a scaffold that resulted in an elongation complex which was 
advanced by one position was prepared (scaffold B, Figure 6-9). Also incubation of this 
complex B with individual NTPs revealed AMP misincorporation (Scaffold B, Figure 
6-10). 
6.6.2 Impaired entry of lesions into the active site 
If the AMP misincorporation is templated by the lesion, the lesion must adopt a 
position in the active site, at least transiently. However, structural considerations 
suggest that lesion entry into the active site would be impaired, because translocation of 
the cisplatin dinucleotide lesion from positions +2/+3 to positions +1/+2 is expected to 
be disfavored, as is the case for a dinucleotide photolesion[206]. Template bases in 
positions +1/+2 are twisted against each other by about 90° in structures of the 
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undamaged elongation complex[178, 207], but such twisting is impossible for nucleotides 
that are covalently linked in dinucleotide lesions, giving rise to a translocation 
barrier[206]. To determine whether translocation of the cisplatin lesion is indeed 
impaired complex B was crystallized. The lesion was designed to be placed at positions 
+1/+2 (scaffold B, Figure 6-9). The anomalous difference Fourier map revealed a 
platinum peak at the same location where one was seen in complex A. This indicates 
that the polymerase had apparently stepped backward by one position, placing the 
cisplatin lesion again at positions +2/+3 (Figure 6-11 A). A lower height of the 
platinum peak indicated partial occupancy of the nucleic acids. Indeed, the electron 
density for the nucleic acids was weak and fragmented, and did not allow for model-
building. Thus, the cisplatin lesion was not stably accommodated at positions +1/+2, 
showing that translocation from positions +2/+3 to positions +1/+2 is apparently 
disfavored. 
 
 
 
Figure 6-11. Anomalous difference Fourier maps of RNAP II elongation complexes B (A) and C (B), 
contoured at 6σ. Model of complex A is shown, viewed from the side. 
 
These results suggest that the lesion does not stably bind the active site at all. To test 
this, a scaffold that contained the lesion at predicted positions -1/+1 in the active site, 
and a G A mismatch pair at position -1 (scaffold C, Figure 6-9) was prepared. The  
resulting complex C was crystallized, however the anomalous difference Fourier map 
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revealed a platinum peak at the same location as in complexes A and B. This  indicated 
that the polymerase had stepped backward by two positions so that the cisplatin lesion 
again occupied positions +2/+3 (Figure 6-11 B). The height of the platinum peak was 
lower than for complexes A and B, and the electron density for the nucleic acids was 
again fragmented, preventing model-building. The attempt to solve a structure with the 
lesion placed at positions -2/-1 (scaffold D, Figure 6-9) resulted in a crystal structure 
with no electron density for nucleic acids. This again was consistent with a low affinity 
of this scaffold for the polymerase. Thus, the cisplatin lesion was not stably 
accommodated in the active site. 
 
6.6.3 Possible mechanisms for misincorporation 
As the template strand in our scaffold contained a thymidine immediately downstream 
of the cisplatin lesion, AMP misincorporation may have arisen from template 
misalignment, a recently characterized mechanism for misincorporation of 
nucleotides[224]. During misalignment, the cisplatin lesion would transiently adopt a 
flipped-out, extrahelical conformation, and the thymidine flanking the lesion on the 5' 
side would transiently occupy the position of the template base, at register +1 in the 
active site, to direct AMP incorporation. To test whether this was the case, a scaffold 
that was identical to scaffold A except that the flanking thymidine was replaced by 
cytidine (scaffold AT C, Figure 6-9) was prepared. This altered scaffold gave rise to the 
same RNA-extension products, showing that template misalignment did not occur. This 
was also confirmed by altering scaffold B (scaffold BT C, Figure 6-9) and repeating the 
RNA-extension assay[225]. 
Another possible explanation for AMP misincorporation is that the 3'-guanosine of the 
lesion could act as a templating base by adopting a position that allows it to form two 
hydrogen bonds with the Watson-Crick positions of an incoming ATP substrate (Figure 
6-12 B). To test whether the third Watson-Crick position of the 3'-guanosine in the 
lesion, the extracyclic 2-amino group, is involved in templating AMP misincorporation, 
we replaced the 3'-guanosine in the lesion with inosine, which lacks the 2-amino group 
(Figure 6-12 B). RNA-extension analysis showed that AMP was still specifically 
misincorporated when scaffolds A and B were modified by replacement of the GG 
cisplatin lesion with an IG cisplatin lesion (Figure 6-12 A). Thus, AMP 
misincorporation does not involve the 2-amino group. These results were still 
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consistent with lesion-templated misincorporation involving a G A base pair (Figure 
6-12 B), but this could not be tested directly. 
 
 
 
Figure 6-12. A: The 2-amino group at the 3' position of the lesion is not involved in directing 
misincorporation. Altered scaffolds were used in RNA-extension assays in which the guanosine at the 3' 
position of the lesion was replaced by inosine. B: Possible base pair formation. Hydrogen bonds are 
indicated with dashed lines. 
 
6.6.4 Nontemplated AMP incorporation and an 'A-rule' for RNAP II 
The crystallographic data strongly suggest impairment of translocation of the lesion to 
a position where it can direct AMP misincorporation. Could AMP incorporation be a 
result of nontemplated synthesis? Such preferential, nontemplated AMP incorporation 
occurs when DNA polymerases encounter a bulky DNA lesion and is known as 
A-rule[209, 210]. To test this hypothesis, a scaffold identical to scaffold B, but containing 
an abasic site at the templating position +1 and containing no cisplatin lesion (scaffold 
Babasic, Figure 6-9) was prepared. Indeed, AMP, and also to a lesser extent GMP, could 
be incorporated into RNA opposite the abasic position (Figure 6-13), showing that 
RNAP II incorporates purine nucleotides, preferentially AMP, when a templating base 
is unavailable. Moreover, the efficiency of nontemplated AMP incorporation was 
comparable to that of the terminal AMP misincorporation during stalling at a cisplatin 
lesion, as judged from the slow rate of the reaction and its dependence on NTP 
concentration[225]. 
These observations suggest that RNAP II obeys an 'A-rule' for nontemplated nucleotide 
addition, which could explain the terminal AMP incorporation when the bulky cisplatin 
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lesion is encountered. This mechanism is consistent with the model in which the 
cisplatin lesion does not enter the active site during elongation, not even transiently to 
direct terminal AMP incorporation. 
 
 
 
 
Figure 6-13. Nontemplated purine incorporation at an abasic site. The scaffold used corresponds to 
scaffold B but contains an abasic site at the templating position +1 and no cisplatin lesion. 
 
6.6.5 Comparison to TT dimer damage recognition 
Comparison of the results with the previously established mechanism of RNAP II 
stalling at a TT dimer reveals that RNAP II stalls at the two dinucleotide lesions for 
different reasons (Figure 6-14). First, the cisplatin lesion cannot overcome the 
translocation barrier, but the TT dimer can. Second, inefficient AMP incorporation 
occurs at both lesions, but it enables lesion binding at the active site positions -1/+1 
only for the CPD, probably because a stabilizing T-A base pair is formed at position -1, 
in contrast to a G-A mismatch that would be formed at the cisplatin lesion. One should 
keep in mind that although primer extension studies reveiled a correct incorporation of 
an A opposite the 3’ T of the TT dimer, in the structure itself the lesion was located 
outside the active center[206]. In the case of the cisplatin lesion, which is also located 
outside the active center, RNAP II incorporates an A opposite an abasic site, 
conforming to the A-rule[209, 210].  Even a slight bias for an A in base pairing at a series 
of consecutive steps could result in a cumulative large preference for As[226], so the 
incorporation of an A opposite the TT dimer might also follow the A-rule, resulting in a 
stabalizing T-A base pair. In this case a correct incorporation is achieved and the lesion 
can be translocated. One could easily test this hypothesis by conducting primer 
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extension studies with a CC dimer and check whether a G or an A is incorporated 
opposite the lesion. An incorporation of an A could then be contributed to the A-rule. 
 
 
 
Figure 6-14. A: RNAP II stalling at the cisplatin lesion, shown as a schematic representation of RNA 
extension in complex A. The initial RNA (top) corresponds to the unextended RNA of scaffold A. 
Dashed line represents translocation barrier. The artificial conditions leading to lesion bypass are 
depicted at the bottom. B: RNAP II stalling at a CPD lesion[206].  
 
Third, UMP misincorporation occurs opposite the 5' nucleotide of the CPD, whereas 
correct incorporation occurs opposite the 5' nucleotide of the cisplatin lesion, but only 
if the lesion is artificially placed beyond the translocation barrier. Fourth, AMP 
misincorporation at the cisplatin lesion is not required for stalling, but CPD-directed 
UMP misincorporation is required for stalling. Finally, the misincorporated nucleotide 
opposite the cisplatin lesion can be bypassed, whereas the misincorporated nucleotide 
opposite the CPD cannot. 
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6.7 Future perspectives and outlook 
Platinum anticancer agents are widely used in cancer chemotherapy. These platinum 
complexes appear to kill dividing cells by forming platinum-DNA adducts which 
interfere with DNA replication, transcription and cell division. These agents form bulky 
DNA adducts which are thought to exert their cytotoxic effect by blocking DNA 
replication. Translesion synthesis, one of the pathways of postreplication repair, is 
thought to account for some resistance to DNA damage and much of the mutagenicity 
of bulky DNA adducts in dividing cells. The most efficient polymerase identified to 
date for the bypass of platinum-DNA adducts is Pol η. 
Our data may guide chemistry programs directed to block the translesion synthesis of 
Pol η across Pt-GG lesions for example by using dinuclear Pt-complexes or complexes, 
which are sterically more demanding. Investigation of such compounds may allow 
deciphering the biological importance of translesion synthesis for the development of 
cancer resistances and may even allow overcoming these problems.  
 
Pol η is able to bypass a variety of interstrand crosslinks. Primery results with a site 
specific 1, 3 oxaliplatin GTG lesion suggest that Pol η can bypass this lesion quite 
efficiently. Detailed primer extension experiments with Michaelis-Menten kinetics 
should be undertaken for each of the 3 bases involved in this lesion. 
 
In conclusion, crystallizing Pol η in ternary complex with a TT dimer containing 
template – primer, the native substrate of Pol η, might shed further light on the 
translesion synthesis exhibited by this unique polymerase. First diffracting crystals 
have actually already beeen obtained for the 3’dT elongation step, although further 
work is needed for obtaining diffracting crystals for the step opposite the 5’dT. 
Furthermore other lesions such as 8-oxoG or 6-OMeG can be crystallized in ternary 
complex with Pol η, following the protocol which was established during this work. 
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7 Appendix 
7.1 Abbreviations 
Å  Angstrom (1 Å = 10-10 m) 
A  adenosine 
ACN  acetonitrile 
BER  Base excision repair 
bp  base pairs 
C  cytosine 
CCD  charge-coupled device 
cp  cisplatin 
CPD  cyclobutane pyrimidine dimer 
CPG  controlled pore size glass 
CV  column volume 
dATP  2’-deoxyadenosine 5’-triphosphate 
dCTP  2’-deoxycytidine 5’-triphosphate 
ddATP  2',3'-dideoxyadenosine 5'-triphosphate 
ddCTP  2',3'-dideoxycytidine 5'-triphosphate 
ddH2O  double distilled water 
ddNTP  2',3'-dideoxynucleoside 5'-triphosphate 
dGTP  2’-deoxyguanosine 5’-triphosphate 
DCM  dichloromethane 
DNA  deoxyribonucleic acid 
dNTP  2’-deoxynucleoside 5’-triphosphate 
ds  double strand 
dTTP  2’-deoxythymidine 5’-triphosphate 
G  guanine 
g  gram 
HPLC  High Performance Liquid Chromatography 
I  inosine 
kV  kilovolt 
m  meter 
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MALDI-TOF Matrix Assisted Laser Desorption Ionization- Time of Flight 
ml  millilitres 
mM  milimolar 
mRNA  messenger RNA 
ms  miliseconds 
NER  Nucleotide excision repair 
PCNA  Proliferating Cell Nuclear Antigen 
PCR  polymerase chain reaction 
Peg 3350 polyethyleneglycol 3350 
pol  polymerase 
Pol η  DNA polymerase η 
RNA  ribonucleic acid 
RNAP  RNA polymerase 
RPA  replication protein A 
rRNA  ribosomal RNA 
SDS  sodium dodecyl sulfate 
snRNA small nuclear RNA 
ss  single strand 
T  thymine 
TLS  translesion synthesis 
TT dimer cis-syn thymine dimer 
UV  ultraviolet 
μl  microliter 
μM  micromolar 
w/v  weight per volume 
V  Volt 
W  Watt 
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7.2 Crystallographic tables 
Table 7.1. Crystallographic table of Pol η with CP containing DNA and ddCTP 
 
 3’dG elongation 
    with ddCTP 
Crystallographic data collection and analysis 
Space group P41212 
Cell dimensions    
    a, b, c (Å) a=b=103.5 
c= 292.1 
    α, β, γ  (°) 90, 90, 90 
  
X-ray source  
Wavelength 1.0702 
Resolution (Å) 3.3 
aRsym  13.0 
I / σI 15.03 
Completeness (%) 99.8 
Redundancy 7.02 
  
Refinement  
Resolution (Å) 20-3.3 
No. reflections 24,769 
bRwork / cRfree 22.0 / 29.8 
No. atoms  
    Protein 9066 
    Ligand/ion DNA-template-primer 
2 ddCTP 
4 calcium 
    Water 92 
  
a R
sym 
is the unweighted R value on I between symmetry mates 
b R
work 
= Σ
hkl
║F
obs
(hkl)│-│F
calc
(hkl)║/ Σ
hkl
│F
obs
(hkl)│ 
c Rfree = the cross validation R factor for 8% of reflections against which the model was not refined 
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Table 7.2: Crystallographic table of Pol η with CP containing template-ddprimer 
DNA  
 
 First crystal 3’dG elongation 
Second crystal 
5’dG elongation 
Crystallographic data collection and analysis 
Space group P41212 P41212 
Cell dimensions     
    a, b, c (Å) a=b=104.1 c= 293.0 
a=b=103.7 
c= 292.8 
    α, β, γ  (°) 90, 90, 90 90, 90, 90 
   
X-ray source PX (SLS) PX (SLS) 
Wavelength 0.8726 1.07190 
Resolution (Å) 3.1 3.3 
Rsyma  15.4 (44.3) 14.7 (44.4) 
I / σI 16.98 (5.71) 11.78 (4.48) 
Completeness (%) 99.6 (97.9) 98.4 (98.1) 
Redundancy 14.2 (13.8) 5.5 (5.5) 
   
Refinement   
Resolution (Å) 20-3.1 25-3.3 
No. reflections 30,031 24,793 
Rworkb / Rfreec 21.9 / 27.2 24.2 / 28.25 
No. atoms   
    Protein 8118 8118 
    Ligand/ion 
DNA- template-dd primer 
2 dCTP 
4 calcium 
DNA-template-dd primer 
2 dATP 
4 calcium 
    Water 121 - 
B-factors   
    Protein 33.1 32.3 
        DNA     46.65 60.03 
    dNTP 31.16 23.24 
    Ca 33.6 27.7 
    water 30.89 - 
R.m.s deviations   
    Bond lengths (Å) 0.00415 0.00887 
    Bond angles (°) 1.20265 1.33389 
 
a R
sym 
is the unweighted R value on I between symmetry mates 
b R
work 
= Σ
hkl
║F
obs
(hkl)│-│F
calc
(hkl)║/ Σ
hkl
│F
obs
(hkl)│ 
c Rfree = the cross validation R factor for 8% of reflections against which the model was not refined 
 
Coordinates and structure factors have been deposited for the 3’ and 5’dG complexes in 
the Protein Data Bank under accession codes 2R8J and 2R8K. 
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